WO1991009966A1 - Cd4 specific recombinant antibody - Google Patents
Cd4 specific recombinant antibody Download PDFInfo
- Publication number
- WO1991009966A1 WO1991009966A1 PCT/GB1990/002015 GB9002015W WO9109966A1 WO 1991009966 A1 WO1991009966 A1 WO 1991009966A1 GB 9002015 W GB9002015 W GB 9002015W WO 9109966 A1 WO9109966 A1 WO 9109966A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cdr
- antibody
- grafted
- chain
- derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK91901835.8T DK0460178T3 (en) | 1989-12-21 | 1990-12-21 | CD4-specific recombinant antibody |
DE69031591T DE69031591T2 (en) | 1989-12-21 | 1990-12-21 | CD4-SPECIFIC RECOMBINANT ANTIBODY |
EP91901835A EP0460178B1 (en) | 1989-12-21 | 1990-12-21 | Cd4 specific recombinant antibody |
CA002046904A CA2046904C (en) | 1989-12-21 | 1990-12-21 | Cd4 specific recombinant antibody |
HU752/91A HU217693B (en) | 1989-12-21 | 1990-12-21 | Process for producing specific recombinant cd4 antibodies |
SU5001870A RU2112037C1 (en) | 1989-12-21 | 1990-12-21 | Hybrid monoclonal antibody interacting with human t-helper cell cd4-antigen and a method of its preparing |
RO148283A RO114980B1 (en) | 1989-12-21 | 1990-12-21 | Antibody molecule capable of binding to the cd4 antigen, nucleotide sequence, process for preparing and method of treatment |
KR1019910700944A KR100191152B1 (en) | 1989-12-21 | 1990-12-21 | Cd4 specific recombinant antibody |
JP50210791A JP3452062B2 (en) | 1989-12-21 | 1990-12-21 | CDR-transplanted antibody |
FI913932A FI108917B (en) | 1989-12-21 | 1991-08-20 | A method for the preparation of a therapeutically useful recombinant CD4 specific antibody |
NO19913271A NO310560B1 (en) | 1989-12-21 | 1991-08-20 | Process for producing a humanized OKT 4a antibody |
GR970403432T GR3025781T3 (en) | 1989-12-21 | 1997-12-24 | Cd4 specific recombinant antibody |
FI990875A FI109768B (en) | 1989-12-21 | 1999-04-19 | New CD4 specific recombinant - complementarily determining region grafted antibody for treating graft rejection and T cell disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898928874A GB8928874D0 (en) | 1989-12-21 | 1989-12-21 | Humanised antibodies |
GB8928874.0 | 1989-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991009966A1 true WO1991009966A1 (en) | 1991-07-11 |
Family
ID=10668300
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1990/002018 WO1991009968A1 (en) | 1989-12-21 | 1990-12-21 | Cd3 specific recombinant antibody |
PCT/GB1990/002015 WO1991009966A1 (en) | 1989-12-21 | 1990-12-21 | Cd4 specific recombinant antibody |
PCT/GB1990/002017 WO1991009967A1 (en) | 1989-12-21 | 1990-12-21 | Humanised antibodies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1990/002018 WO1991009968A1 (en) | 1989-12-21 | 1990-12-21 | Cd3 specific recombinant antibody |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1990/002017 WO1991009967A1 (en) | 1989-12-21 | 1990-12-21 | Humanised antibodies |
Country Status (21)
Country | Link |
---|---|
US (10) | US5929212A (en) |
EP (5) | EP0620276A1 (en) |
JP (4) | JP3242913B2 (en) |
KR (3) | KR100197956B1 (en) |
AT (4) | ATE208794T1 (en) |
AU (4) | AU646009B2 (en) |
BG (1) | BG60462B1 (en) |
BR (1) | BR9007197A (en) |
CA (3) | CA2046904C (en) |
DE (4) | DE69020544T2 (en) |
DK (4) | DK0460167T3 (en) |
ES (4) | ES2079638T3 (en) |
FI (4) | FI108917B (en) |
GB (4) | GB8928874D0 (en) |
GR (2) | GR3017734T3 (en) |
HU (4) | HU217693B (en) |
NO (5) | NO316076B1 (en) |
RO (3) | RO114232B1 (en) |
RU (1) | RU2112037C1 (en) |
WO (3) | WO1991009968A1 (en) |
ZA (1) | ZA9110129B (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992005274A1 (en) * | 1990-09-17 | 1992-04-02 | Scott David Gorman | Framework mutated antibodies and their preparation |
WO1992015699A1 (en) * | 1991-03-04 | 1992-09-17 | Ks Biomedix Ltd. | High affinity humanized monoclonal antibodies |
WO1996036359A1 (en) * | 1995-05-18 | 1996-11-21 | Ortho Pharmaceutical Corporation | Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies |
US5585097A (en) * | 1992-03-24 | 1996-12-17 | British Technology Group Limited | Humanized anti-CD3 specific antibodies |
WO1997017374A1 (en) * | 1995-11-08 | 1997-05-15 | Medac Gesellschaft Für Klinische Spezialpräparate Gmbh | Recombinant ligands for the human cell membrane antigen cd30 |
US5821337A (en) * | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
US5871732A (en) * | 1990-11-27 | 1999-02-16 | Biogen, Inc. | Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection |
US6054297A (en) * | 1991-06-14 | 2000-04-25 | Genentech, Inc. | Humanized antibodies and methods for making them |
US6180370B1 (en) | 1988-12-28 | 2001-01-30 | Protein Design Labs, Inc. | Humanized immunoglobulins and methods of making the same |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US7037496B2 (en) | 1989-12-27 | 2006-05-02 | Centocor, Inc. | Chimeric immunoglobulin for CD4 receptors |
JP2008189691A (en) * | 1995-10-10 | 2008-08-21 | Genpharm Internatl Inc | Transgenic non-human animal producing heterologous antibody |
WO2008110332A1 (en) | 2007-03-13 | 2008-09-18 | F.Hoffmann-La Roche Ag | Peptide-complement conjugates |
WO2009012944A1 (en) | 2007-07-20 | 2009-01-29 | F.Hoffmann-La Roche Ag | A conjugate of an antibody against cd4 and antifusogenic peptides |
US7951920B2 (en) | 2006-08-17 | 2011-05-31 | Roche Palo Alto Llc | Conjugate of an antibody against CCR5 and an antifusogenic peptide |
EP2363484A3 (en) * | 1998-04-03 | 2012-04-25 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody |
WO2012166555A1 (en) | 2011-05-27 | 2012-12-06 | Nektar Therapeutics | Water - soluble polymer - linked binding moiety and drug compounds |
US8663634B2 (en) | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
US9056906B2 (en) | 2006-06-14 | 2015-06-16 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
US9334325B2 (en) | 2008-03-13 | 2016-05-10 | Biotest Ag | Method for treating psoriasis |
US9505829B2 (en) | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
US9512226B2 (en) | 2008-03-13 | 2016-12-06 | Biotest Ag | Agent for treating disease |
US9550831B2 (en) | 2008-03-13 | 2017-01-24 | Biotest Ag | Method for treating psoriasis |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
US9995733B2 (en) | 2009-11-30 | 2018-06-12 | Biotest Ag | Agents for treating disease |
US10669337B2 (en) | 2014-07-25 | 2020-06-02 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
US10729742B2 (en) | 2007-02-01 | 2020-08-04 | Universitätsmedizin Der Johannes Gutenberg-Universität Mainz | Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4 |
US10982002B2 (en) | 2018-03-12 | 2021-04-20 | Zoetis Services Llc | Anti-NGF antibodies and methods thereof |
US11161906B2 (en) | 2013-07-25 | 2021-11-02 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
Families Citing this family (1260)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800815A (en) * | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
CU22545A1 (en) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
DE69032484D1 (en) * | 1989-10-27 | 1998-08-20 | Arch Dev Corp | COMPOSITIONS AND THE USE THEREOF TO PROMOTE IMMUNOPOTENTIATION |
US6750325B1 (en) * | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
GB9021679D0 (en) * | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
US6399062B1 (en) * | 1990-11-06 | 2002-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Murine monoclonal antibody protective against Plasmodium vivax malaria |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
DK0610201T4 (en) * | 1991-03-18 | 2008-02-04 | Centocor Inc | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
ES2134212T3 (en) | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | HUMAN ANTIBODY RECONSTITUTED AGAINST THE RECEIVER OF INTERLEUKIN 6 HUMAN. |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US6329509B1 (en) | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
US6699472B2 (en) | 1991-08-14 | 2004-03-02 | Genentech, Inc. | Method of treating allergic disorders |
ES2145004T3 (en) * | 1991-08-21 | 2000-07-01 | Novartis Ag | DERIVATIVES OF ANTIBODIES. |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
GB9120467D0 (en) * | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
JPH05244982A (en) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | Humanized b-b10 |
GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
AU3236793A (en) * | 1991-12-12 | 1993-07-19 | Berlex Laboratories, Inc. | Recombinant and chimeric antibodies to c-erbB-2 |
US5635177A (en) | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
US5837822A (en) * | 1992-01-27 | 1998-11-17 | Icos Corporation | Humanized antibodies specific for ICAM related protein |
AU675929B2 (en) * | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US7381803B1 (en) * | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
EP0563487A1 (en) | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
US5646253A (en) * | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
US6033667A (en) * | 1992-05-05 | 2000-03-07 | Cytel Corporation | Method for detecting the presence of P-selectin |
DE4225853A1 (en) * | 1992-08-05 | 1994-02-10 | Behringwerke Ag | Granulocyte-binding antibody fragments, their production and use |
US6042828A (en) * | 1992-09-07 | 2000-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
GB9221654D0 (en) * | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant human anti-cytomegalovirus antibodies |
GB9223377D0 (en) * | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
US5804187A (en) * | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
CA2153692C (en) | 1993-01-12 | 2011-11-08 | Roy R. Lobb | Recombinant anti-vla4 antibody molecules |
US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
EP0728017A1 (en) * | 1993-11-10 | 1996-08-28 | Bristol-Myers Squibb Company | Treatment of bacterially-induced inflammatory diseases |
EP0729976A1 (en) * | 1993-11-19 | 1996-09-04 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
WO1995023865A1 (en) * | 1994-03-03 | 1995-09-08 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
US5597710A (en) * | 1994-03-10 | 1997-01-28 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
CA2186455A1 (en) * | 1994-03-29 | 1995-10-05 | Raymond John Owens | Antibodies against e-selectin |
WO1995031546A1 (en) * | 1994-04-28 | 1995-11-23 | Scotgen Biopharmaceuticals, Inc. | Recombinant human anti-varicella zoster virus antibodies |
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
GB9412230D0 (en) * | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
USRE39548E1 (en) * | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
US8771694B2 (en) * | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
GB9424449D0 (en) * | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
WO1996020281A1 (en) | 1994-12-23 | 1996-07-04 | Celltech Therapeutics Limited | Human phosphodiesterase type ivc, and its production and use |
ES2197217T3 (en) * | 1994-12-28 | 2004-01-01 | University Of Kentucky Research Foundation | 3H1 ANTI-ID-MURINO MONOCLONAL ANTIBODY. |
US6949244B1 (en) * | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US5795961A (en) * | 1995-02-14 | 1998-08-18 | Ludwig Institute For Cancer Research | Recombinant human anti-Lewis b antibodies |
US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
PT833911E (en) * | 1995-06-07 | 2004-09-30 | Ortho Mcneil Pharm Inc | ANTI-FACTOR ANTI-FACTOR ANTI-FACTOR CUTTED WITH CDR AND METHODS FOR THEIR USE |
US5712374A (en) * | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US5977322A (en) * | 1995-06-14 | 1999-11-02 | The Regents Of The University Of California | High affinity human antibodies to tumor antigens |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
MA24512A1 (en) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | PROCESS FOR THE PREPARATION OF ANTICOAGULATING AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS |
RU2270030C2 (en) * | 1996-02-09 | 2006-02-20 | Абботт Байотекнолоджи эЛтиди. | METHOD AND OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT FOR INHIBITING HUMAN TNFα ACTIVITY, APPLYING THE OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT AS INGREDIENT FOR PRODUCING MEDICAMENT |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
JP4503706B2 (en) | 1996-06-07 | 2010-07-14 | ポニアード ファーマシューティカルズ,インコーポレイティド | Humanized antibodies with modified glycosylation |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US6114506A (en) * | 1996-09-20 | 2000-09-05 | General Hospital Corporation | Composition and method for enhancing fibrinolysis |
UA76934C2 (en) * | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
US7883872B2 (en) | 1996-10-10 | 2011-02-08 | Dyadic International (Usa), Inc. | Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose |
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US6737057B1 (en) * | 1997-01-07 | 2004-05-18 | The University Of Tennessee Research Corporation | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
US6455040B1 (en) | 1997-01-14 | 2002-09-24 | Human Genome Sciences, Inc. | Tumor necrosis factor receptor 5 |
US6342363B1 (en) | 1997-01-28 | 2002-01-29 | Human Genome Sciences, Inc. | Death domain containing receptor 4 nucleic acids and methods |
US8329179B2 (en) | 1997-01-28 | 2012-12-11 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
US7452538B2 (en) | 1997-01-28 | 2008-11-18 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
US6433147B1 (en) | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
NZ508381A (en) * | 1997-03-17 | 2002-09-27 | Human Genome Sciences Inc | Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5) |
US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
EP3260468A1 (en) * | 1997-04-07 | 2017-12-27 | Genentech, Inc. | Anti-vegf antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
EP0973804B1 (en) * | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
RU2221809C2 (en) * | 1997-10-03 | 2004-01-20 | Тугаи Сейяку Кабусики Кайся | Method for preparing natural humanized antibody |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
EP1982990A1 (en) | 1998-03-19 | 2008-10-22 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
PT1071752E (en) * | 1998-04-21 | 2003-11-28 | Micromet Ag | SPECIFIC POLYMPEPTIDES FOR CD19XCD3 AND ITS USES |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
JP2002512776A (en) * | 1998-04-28 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | Monoclonal antibodies with reduced immunogenicity |
US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
GB9815909D0 (en) * | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US6727349B1 (en) | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
DK1117808T3 (en) | 1998-10-06 | 2005-04-25 | Mark Aaron Emalfarb | Transformational system before comparing the area of filamentous fungal hosts: In the chrysosporium |
US6160099A (en) * | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
US6395511B1 (en) | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
CA2363779A1 (en) | 1999-02-26 | 2000-08-31 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
AU782115B2 (en) * | 1999-09-22 | 2005-07-07 | Ortho-Mcneil Pharmaceutical, Inc. | Cell based assay |
DE60038252T2 (en) * | 1999-09-30 | 2009-03-19 | Kyowa Hakko Kogyo Co., Ltd. | Human antibody against ganglioside GD3 for the transplantation completeity determining region and derivatives of the anti-ganglioside GD3 antibody |
US6342587B1 (en) * | 1999-10-22 | 2002-01-29 | Ludwig Institute For Cancer Research | A33 antigen specific immunoglobulin products and uses thereof |
US6346249B1 (en) * | 1999-10-22 | 2002-02-12 | Ludwig Institute For Cancer Research | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products |
CU22921A1 (en) * | 1999-11-16 | 2004-02-20 | Centro Inmunologia Molecular | CHEMICAL, HUMANIZED ANTIBODIES AND THE SIMPLE CHAIN FV TYPE FRAGMENT RECOGNIZING ANTIGEN C2. ITS USE IN THE DIAGNOSIS AND TREATMENT OF COLORECTURAL TUMORS |
GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
US6656467B2 (en) * | 2000-01-27 | 2003-12-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
AU2002219944B2 (en) | 2000-11-28 | 2008-02-21 | Medimmune, Llc | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
EP1783227A1 (en) * | 2000-02-03 | 2007-05-09 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
AU2001233277B2 (en) * | 2000-02-03 | 2004-06-03 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
CA2399387C (en) | 2000-02-11 | 2015-11-03 | Biogen, Inc. | Heterologous polypeptide of the tnf family |
TR200202799T3 (en) | 2000-02-24 | 2003-03-21 | Washington University St.Louis | Humanized antibodies that sequence the AB peptide |
ES2390761T3 (en) * | 2000-03-01 | 2012-11-16 | Medimmune, Llc | Recombinant high-potency antibodies and method for their production |
US20030143226A1 (en) * | 2000-03-02 | 2003-07-31 | Yuko Kobayashi | Human monoclonal antibodies against oxidized ldl receptor and medicinal use thereof |
EP1267926A2 (en) | 2000-03-17 | 2003-01-02 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
EP1276849A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
AU4884001A (en) | 2000-04-21 | 2001-11-07 | Fuso Pharmaceutical Ind | Novel collectins |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
WO2001096528A2 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
PT2275449T (en) | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
UA81743C2 (en) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US7060802B1 (en) | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
JP2004532608A (en) | 2000-10-13 | 2004-10-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Humanized anti-LT-β-R antibody |
US6989247B2 (en) | 2000-11-28 | 2006-01-24 | Celltech R & D, Inc. | Compositions and methods for diagnosing or treating psoriasis |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
PE20020574A1 (en) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
AR032028A1 (en) | 2001-01-05 | 2003-10-22 | Pfizer | ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2002251913A1 (en) * | 2001-02-02 | 2002-08-19 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
JP2005503116A (en) | 2001-02-09 | 2005-02-03 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Human G protein chemokine receptor (CCR5) HDGNR10 |
EP1998266A3 (en) | 2001-02-19 | 2009-02-11 | Merck Patent GmbH | Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity |
ES2619313T3 (en) * | 2001-03-15 | 2017-06-26 | Precision Biologics, Inc. | Monoclonal antibody therapy for pancreatic cancer |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
DE60236646D1 (en) | 2001-04-13 | 2010-07-22 | Human Genome Sciences Inc | Anti-VEGF-2 antibodies |
WO2002097033A2 (en) | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US6867189B2 (en) | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
JP4729717B2 (en) † | 2001-08-03 | 2011-07-20 | 株式会社医学生物学研究所 | Antibody that recognizes GM1 ganglioside-binding amyloid β protein, and DNA encoding the antibody |
DK1944040T3 (en) | 2001-08-17 | 2012-10-29 | Univ Washington | Method of analysis for Alzheimer's disease |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
DE60238497D1 (en) * | 2001-09-14 | 2011-01-13 | Fraunhofer Ges Forschung | IMMUNOGLOBULIN WITH A PARTICULAR FRAME SCAFFOLD AND METHOD FOR THE PRODUCTION AND USE THEREOF |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
EP1444267B1 (en) * | 2001-10-15 | 2016-08-10 | Immunomedics, Inc. | Affinity enhancement agents |
CA2463927A1 (en) * | 2001-10-16 | 2003-04-24 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
AU2002365926A1 (en) * | 2001-10-25 | 2003-09-02 | Euro-Celtique S.A. | Compositions and methods directed to anthrax toxin |
JP2005512043A (en) * | 2001-12-03 | 2005-04-28 | アブジェニックス・インコーポレーテッド | Discovery of therapeutic products |
US7771951B2 (en) * | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
EP1554576B9 (en) * | 2001-12-03 | 2008-08-20 | Amgen Fremont Inc. | Identification of high affinity molecules by limited dilution screening |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
JP2005535572A (en) | 2002-04-12 | 2005-11-24 | メディミューン,インコーポレーテッド | Recombinant anti-interleukin-9 antibody |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
AU2003225237A1 (en) | 2002-05-01 | 2003-11-17 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine beta-4 |
AU2012244218C1 (en) * | 2002-05-02 | 2016-12-15 | Wyeth Holdings Llc. | Calicheamicin derivative-carrier conjugates |
HUE030806T2 (en) * | 2002-05-02 | 2017-05-29 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
ATE518885T1 (en) | 2002-05-28 | 2011-08-15 | Ucb Pharma Sa | PEG POSITION ISOMER OF AN ANTIBODY TO TNFALPHA (CDP870) |
NZ537579A (en) | 2002-06-10 | 2006-10-27 | Vaccinex Inc | C35 peptide epitopes and their analogs |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7456260B2 (en) | 2002-06-17 | 2008-11-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Humanized antibody |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
JP2005532051A (en) | 2002-07-01 | 2005-10-27 | バイオジェン, インコーポレイテッド | Humanized anti-lymphotoxin β receptor antibody |
AU2003267999B2 (en) * | 2002-07-19 | 2010-03-11 | Abbvie Biotechnology Ltd | Treatment of TNFalpha related disorders |
EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
WO2004019886A2 (en) | 2002-08-29 | 2004-03-11 | Cytocure Llc | Methods for up-regulating antigen expression in tumors |
CA2501616C (en) | 2002-10-08 | 2015-05-12 | Immunomedics, Inc. | Antibody therapy |
EP1551876B1 (en) | 2002-10-16 | 2011-03-16 | Purdue Pharma L.P. | Antibodies that bind cell-associated ca 125/0722p and methods of use thereof |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
WO2004110345A2 (en) * | 2002-10-29 | 2004-12-23 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
WO2004039845A1 (en) * | 2002-10-31 | 2004-05-13 | Universita'degli Studi Di Roma 'la Sapienza' | Antimicrobial lipase antibodies their nucleotide and aminoacid sequences and uses thereof |
WO2005044858A1 (en) | 2003-11-07 | 2005-05-19 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
JP2006524036A (en) | 2002-11-08 | 2006-10-26 | アブリンクス エン.ヴェー. | Single domain antibodies targeting tumor necrosis factor alpha and uses thereof |
CA2505633A1 (en) * | 2002-11-13 | 2004-05-27 | Raven Biotechnologies, Inc. | Antigen pipa and antibodies that bind thereto |
DE60334246D1 (en) | 2002-11-21 | 2010-10-28 | Celltech R & D Inc | MODULATE IMMUNE RESPONSES |
NZ540562A (en) | 2002-11-26 | 2008-04-30 | Pdl Biopharma Inc | Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis |
WO2004058171A2 (en) | 2002-12-20 | 2004-07-15 | Protein Design Labs, Inc. | Antibodies against gpr64 and uses thereof |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
CA2513113A1 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
KR20050118669A (en) * | 2003-02-01 | 2005-12-19 | 뉴랄랩 리미티드 | Active immunization to generate antibodies to soluble a-beta |
ATE468886T1 (en) * | 2003-02-10 | 2010-06-15 | Applied Molecular Evolution | ABETA-BINDING MOLECULES |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
EP1638587A4 (en) | 2003-02-14 | 2007-04-18 | Univ Missouri | Contraceptive methods and compositions related to proteasomal interference |
JP5356648B2 (en) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス, インコーポレイテッド | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
WO2006113909A2 (en) | 2005-04-19 | 2006-10-26 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
PT2248899E (en) | 2003-03-19 | 2015-09-23 | Biogen Ma Inc | Nogo receptor binding protein |
KR101224235B1 (en) | 2003-04-11 | 2013-01-25 | 메디뮨 엘엘씨 | Recombinant IL-9 Antibodies and Uses Thereof |
WO2004093908A2 (en) | 2003-04-23 | 2004-11-04 | Medarex, Inc. | Compositions and methods for the therapy of inflammatory bowel disease |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
US7605235B2 (en) | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US7635472B2 (en) | 2003-05-31 | 2009-12-22 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
NZ544618A (en) | 2003-06-16 | 2009-02-28 | Celltech R & D Inc | Antibodies specific for sclerostin and methods for increasing bone mineralization |
US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
WO2005010040A1 (en) | 2003-07-15 | 2005-02-03 | Barros Research Institute | Eimeria tenella antigen for immunotherapy of coccidiosis |
JP5105874B2 (en) * | 2003-07-18 | 2012-12-26 | アムジエン・インコーポレーテツド | Specific binding factor for hepatocyte growth factor |
US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
AU2004258955C1 (en) * | 2003-07-21 | 2012-07-26 | Immunogen, Inc. | A CA6 antigen-specific cytotoxic conjugate and methods of using the same |
US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
CA2534661A1 (en) | 2003-08-08 | 2005-02-17 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
KR100825156B1 (en) | 2003-08-13 | 2008-04-24 | 화이자 프로덕츠 인코포레이티드 | - modified human igf-ir antibodies |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
EP2272566A3 (en) | 2003-08-18 | 2013-01-02 | MedImmune, LLC | Humanisation of antibodies |
EP1660534A2 (en) * | 2003-08-22 | 2006-05-31 | MedImmune, Inc. | Humanization of antibodies |
GB0321100D0 (en) | 2003-09-09 | 2003-10-08 | Celltech R&D Ltd | Biological products |
KR101229731B1 (en) * | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | Multispecific deimmunized cd3-binders |
SI1678314T1 (en) | 2003-10-22 | 2013-01-31 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
EP1695093A1 (en) * | 2003-12-05 | 2006-08-30 | multimmune GmbH | Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases |
JP4943161B2 (en) | 2003-12-23 | 2012-05-30 | ジェネンテック, インコーポレイテッド | Treatment of cancer with a novel anti-IL13 monoclonal antibody |
DK1704166T3 (en) | 2004-01-07 | 2015-06-01 | Novartis Vaccines & Diagnostic | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
EP1712566A4 (en) | 2004-01-19 | 2007-09-12 | Medical & Biol Lab Co Ltd | Inflammatory cytokine inhibitor |
BRPI0507026A (en) | 2004-02-09 | 2007-04-17 | Human Genome Sciences Inc | albumin fusion proteins |
EP2340850A1 (en) | 2004-02-10 | 2011-07-06 | The Regents of the University of Colorado, a Body Corporate | Inhibition of factor B, the alternative complement pathway and methods related thereto |
CN1980957A (en) | 2004-03-23 | 2007-06-13 | 比奥根艾迪克Ma公司 | Receptor coupling agents and therapeutic uses thereof |
US7973139B2 (en) | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
TWI439284B (en) * | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | Multiple-variable dose regimen for treating tnfα-related disorders |
US9228008B2 (en) | 2004-05-28 | 2016-01-05 | Idexx Laboratories, Inc. | Canine anti-CD20 antibodies |
CA2570823C (en) | 2004-06-21 | 2015-02-24 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
ES2395094T3 (en) | 2004-06-24 | 2013-02-08 | Biogen Idec Ma Inc. | Treatment of conditions that involve demyelination |
EP1773391A4 (en) * | 2004-06-25 | 2009-01-21 | Medimmune Inc | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
GB0414886D0 (en) | 2004-07-02 | 2004-08-04 | Neutec Pharma Plc | Treatment of bacterial infections |
CA2573821A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
PL1781321T3 (en) * | 2004-08-02 | 2014-07-31 | Zenyth Operations Pty Ltd | A method of treating cancer comprising a vegf-b antagonist |
US7846438B2 (en) | 2004-08-03 | 2010-12-07 | Biogen Idec Ma Inc. | Methods of promoting neurite outgrowth with soluble TAJ polypeptides |
JP4468989B2 (en) | 2004-08-16 | 2010-05-26 | クアーク・ファーマスーティカルス、インコーポレイテッド | Use of RTP801 inhibitors for therapy |
CA2486285C (en) | 2004-08-30 | 2017-03-07 | Viktor S. Goldmakher | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
EP3073267A1 (en) | 2004-09-21 | 2016-09-28 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
EP1812068A4 (en) * | 2004-10-29 | 2010-06-09 | Medimmune Inc | Methods of preventing and treating rsv infections and related conditions |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
WO2006061723A2 (en) | 2004-12-06 | 2006-06-15 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
PE20061401A1 (en) * | 2004-12-15 | 2006-12-23 | Neuralab Ltd | Aß ANTIBODIES TO IMPROVE COGNITION |
TW200636066A (en) * | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized antibodies that recognize beta amyloid peptide |
TW200635607A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized Aβ antibodies for use in improving cognition |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
ES2732623T3 (en) | 2005-01-06 | 2019-11-25 | Innate Pharma Sa | Anti-KIR combination treatments and methods |
EP2520669A3 (en) | 2005-02-07 | 2013-02-27 | GeneNews Inc. | Mild osteoathritis biomarkers and uses thereof |
US20060233791A1 (en) | 2005-02-15 | 2006-10-19 | Duke University | Anti-CD19 antibodies and uses in oncology |
JP2008531730A (en) | 2005-03-04 | 2008-08-14 | キュアーディーエム、インク. | Methods and pharmaceutical compositions for treating type I diabetes mellitus and other conditions |
JP5153613B2 (en) | 2005-03-18 | 2013-02-27 | メディミューン,エルエルシー | Antibody framework shuffle |
JP2008532559A (en) | 2005-03-19 | 2008-08-21 | メディカル リサーチ カウンシル | Treatment and prevention of viral infection or improvement of treatment and prevention |
SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
WO2008157379A2 (en) | 2007-06-21 | 2008-12-24 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
CA2605024C (en) | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
WO2006117910A1 (en) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | Monoclonal antibody against platelet membrane glycoprotein vi |
EP1885755A4 (en) | 2005-05-05 | 2009-07-29 | Univ Duke | Anti-cd19 antibody therapy for autoimmune disease |
MX2007013609A (en) | 2005-05-06 | 2008-01-24 | Zymogenetics Inc | Il-31 monoclonal antibodies and methods of use. |
WO2006121159A1 (en) * | 2005-05-12 | 2006-11-16 | Kyowa Hakko Kogyo Co., Ltd. | Humanized cdr-grafted antibody specifically reacting with cd10 and antibody fragment of the same |
NZ591701A (en) * | 2005-05-16 | 2012-11-30 | Abbott Biotech Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
KR101273829B1 (en) | 2005-05-20 | 2013-06-11 | 론자 바이올로직스 피엘씨 | High-level expression of recombinant antibody in a mammalian host cell |
NZ563392A (en) | 2005-05-20 | 2009-12-24 | Ablynx Nv | Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders |
US7393919B2 (en) | 2005-05-25 | 2008-07-01 | Cure Dm, Inc. | Peptides, derivatives and analogs thereof, and methods of using same |
US8911733B2 (en) | 2005-05-26 | 2014-12-16 | Musc Foundation For Research Development | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
EP2390267B1 (en) * | 2005-06-07 | 2013-06-05 | ESBATech - a Novartis Company LLC | Stable and soluble antibodies inhibiting TNF(alpha) |
KR20080025174A (en) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | Antibody formulations having optimized aggregation and fragmentation profiles |
US7700739B2 (en) | 2005-06-30 | 2010-04-20 | Abbott Laboratories | IL-12/p40 binding proteins |
MX2008000253A (en) | 2005-07-08 | 2008-04-02 | Biogen Idec Inc | Sp35 antibodies and uses thereof. |
US7482124B2 (en) | 2005-07-08 | 2009-01-27 | Bristol-Myers Squibb Company | Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema |
DK1912675T3 (en) | 2005-07-25 | 2014-03-24 | Emergent Product Dev Seattle | B-cell reduction using specific and cd37-cd20-specific binding molecules |
JP5457671B2 (en) | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | M-CSF specific monoclonal antibody and use thereof |
SI2573114T1 (en) | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
EP2500356A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
RU2515108C2 (en) | 2005-08-19 | 2014-05-10 | Эббви Инк | Immunoglobulin with double variable domains and its applications |
AU2006295717B2 (en) | 2005-09-29 | 2012-01-19 | Eisai R & D Management Co., Ltd. | T-cell adhesion molecule and antibody directed against the molecule |
US8906864B2 (en) | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
ATE518007T1 (en) | 2005-10-21 | 2011-08-15 | Genenews Inc | METHOD AND APPARATUS FOR CORRELING LEVELS OF BIOMARKER PRODUCTS WITH DISEASES |
PL2500030T5 (en) | 2005-11-04 | 2019-02-28 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
MX2008005764A (en) | 2005-11-04 | 2008-11-18 | Biogen Idec Inc | Methods for promoting neurite outgrowth and survival of dopaminergic neurons. |
JP5191392B2 (en) | 2005-11-07 | 2013-05-08 | ザ スクリプス リサーチ インスティチュート | Compositions and methods for modulating the specificity of tissue factor signaling |
TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
KR101439828B1 (en) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | Monoclonal antibodies against amyloid beta protein and uses thereof |
JP5312039B2 (en) | 2005-12-02 | 2013-10-09 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Treatment of conditions involving demyelination |
DK1960430T3 (en) | 2005-12-09 | 2015-01-05 | Ucb Pharma Sa | ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMANT IL-6 |
GB0525214D0 (en) | 2005-12-12 | 2006-01-18 | Bioinvent Int Ab | Biological materials and uses thereof |
DK1976880T3 (en) | 2005-12-21 | 2016-09-26 | Amgen Res (Munich) Gmbh | Pharmaceutical compositions with resistance to soluble cea |
EP1991274A4 (en) | 2006-01-20 | 2009-06-10 | Women S And Children S Health | Method of treatment, prophylaxis and diagnosis of pathologies of the bone |
NL2000439C2 (en) | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutic applications of inhibitors of RTP801. |
CN103215293B (en) | 2006-01-27 | 2015-10-28 | 比奥根Ma公司 | NOGO receptor antagonist |
EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
DK1994055T3 (en) | 2006-03-10 | 2014-08-25 | Wyeth Llc | ANTI-5T4 ANTIBODIES AND APPLICATIONS THEREOF |
CN103641915B (en) | 2006-03-27 | 2017-04-12 | 医学免疫有限公司 | Binding member for GM-CSF receptor |
NZ611859A (en) | 2006-04-05 | 2014-12-24 | Abbvie Biotechnology Ltd | Antibody purification |
EP2004231A4 (en) | 2006-04-07 | 2013-07-10 | Nektar Therapeutics | Conjugates of an anti-tnf-alpha antibody |
US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
US9624295B2 (en) | 2006-04-10 | 2017-04-18 | Abbvie Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
WO2007120656A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
WO2007145941A2 (en) * | 2006-06-06 | 2007-12-21 | Tolerrx, Inc. | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
AT503690A1 (en) | 2006-06-09 | 2007-12-15 | Biomay Ag | HYPOALLERGENIC MOLECULES |
EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
LT2029173T (en) * | 2006-06-26 | 2016-11-10 | Macrogenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
RU2499001C2 (en) | 2006-06-30 | 2013-11-20 | Ново Нордиск А/С | Antibodies to nkg2a and their applications |
TWI498137B (en) | 2006-06-30 | 2015-09-01 | Abbvie Biotechnology Ltd | Automatic injection device |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
GB0613209D0 (en) * | 2006-07-03 | 2006-08-09 | Ucb Sa | Methods |
CN101622276B (en) | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | Antagonist antibody against EphA2 for the treatment of cancer |
CN101511868B (en) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | Exendin fusion proteins |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
CA2659820A1 (en) | 2006-08-04 | 2008-02-14 | Novartis Ag | Ephb3-specific antibody and uses thereof |
GEP20125612B (en) | 2006-08-18 | 2012-08-27 | Novartis Ag | Prlr-specific antibody and usage thereof |
EP2064243A2 (en) | 2006-08-28 | 2009-06-03 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic human light-specific human monoclonal antibodies |
CN101522713A (en) | 2006-09-01 | 2009-09-02 | 津莫吉尼蒂克斯公司 | Variable region sequences of IL-31 monoclonal antibodies and methods of use |
ES2902063T3 (en) | 2006-09-08 | 2022-03-24 | Abbvie Bahamas Ltd | Interleukin-13 binding proteins |
JP2010506842A (en) | 2006-10-16 | 2010-03-04 | メディミューン,エルエルシー | Molecules with reduced half-life, compositions thereof and uses |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US20100047247A1 (en) | 2006-11-17 | 2010-02-25 | The Research Foundation For Microbial Diseases Of Osaka University | Nerve elongation promoter and elongation inhibitor |
WO2008064306A2 (en) | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
EP2431053A1 (en) | 2006-11-27 | 2012-03-21 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
EP2687232A1 (en) | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
WO2008070780A1 (en) | 2006-12-07 | 2008-06-12 | Novartis Ag | Antagonist antibodies against ephb3 |
US8680252B2 (en) | 2006-12-10 | 2014-03-25 | Dyadic International (Usa), Inc. | Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi |
US7935791B2 (en) | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
WO2008074839A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
DK2740744T3 (en) | 2007-01-09 | 2018-04-23 | Biogen Ma Inc | Sp35 antibodies and uses thereof |
WO2008098139A2 (en) | 2007-02-07 | 2008-08-14 | The Regents Of The University Of Colorado | Axl tyrosine kinase inhibitors and methods of making and using the same |
EP1958645A1 (en) | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
AR065368A1 (en) | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | ANTIBODIES FOR IGE MOLECULES |
US8685666B2 (en) | 2007-02-16 | 2014-04-01 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies and uses thereof |
US8114606B2 (en) | 2007-02-16 | 2012-02-14 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
NZ580245A (en) | 2007-03-22 | 2012-01-12 | Biogen Idec Inc | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
US8557588B2 (en) * | 2007-03-27 | 2013-10-15 | Schlumberger Technology Corporation | Methods and apparatus for sampling and diluting concentrated emulsions |
JP5456658B2 (en) | 2007-03-30 | 2014-04-02 | メディミューン,エルエルシー | Antibody preparation |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2164868B1 (en) | 2007-05-04 | 2015-03-25 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Engineered rabbit antibody variable domains and uses thereof |
EP2068927B1 (en) | 2007-05-14 | 2015-10-21 | MedImmune, LLC | Methods of reducing eosinophil levels |
AU2007353779B2 (en) | 2007-05-17 | 2013-11-07 | Genentech, Inc. | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
DK2164514T3 (en) | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US20090104187A1 (en) * | 2007-05-21 | 2009-04-23 | Alder Biopharmaceuticals, Inc. | Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
GB0712503D0 (en) * | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
DK2182983T3 (en) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | TREATMENT OF AMYLOIDOGENIC DISEASES WITH HUMANIZED ANTI-ABETA ANTIBODIES |
CA2698203C (en) | 2007-08-29 | 2018-09-11 | Sanofi-Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their use |
NZ599756A (en) | 2007-08-30 | 2013-09-27 | Curedm Group Holdings Llc | Compositions and methods of using proislet peptides and analogs thereof |
EP2185190B1 (en) * | 2007-08-31 | 2015-06-24 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
WO2009033071A2 (en) | 2007-09-07 | 2009-03-12 | Dyadic International, Inc. | Novel fungal enzymes |
US20090136427A1 (en) | 2007-09-18 | 2009-05-28 | La Jolla Institute For Allergy And Immunology | LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment |
EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
RU2542967C2 (en) * | 2007-10-05 | 2015-02-27 | Дженентек, Инк. | Using anti-amyloid beta antibody in ophthalmic diseases |
EP2238166B1 (en) | 2007-10-05 | 2013-11-27 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
AU2008324800B2 (en) | 2007-11-05 | 2014-03-27 | Astrazeneca Ab | Methods of treating scleroderma |
WO2009062112A2 (en) | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
EP2222700A2 (en) | 2007-11-27 | 2010-09-01 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
JP5490714B2 (en) | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | Protein preparation |
US8470979B2 (en) | 2007-12-07 | 2013-06-25 | Zymogenetics, Inc. | Humanized antibody molecules specific for IL-31 |
CN105001333B (en) | 2007-12-14 | 2019-05-17 | 诺沃—诺迪斯克有限公司 | Anti-human NKG2D antibody and application thereof |
EP2801584B1 (en) | 2007-12-26 | 2019-07-10 | Biotest AG | Agents targeting CD138 and uses thereof |
CA2710680C (en) | 2007-12-26 | 2018-10-16 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
US9011864B2 (en) | 2007-12-26 | 2015-04-21 | Biotest Ag | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
JP2011508738A (en) | 2007-12-26 | 2011-03-17 | バイオテスト・アクチエンゲゼルシヤフト | Method and agent for improving targeting of CD138 expressing tumor cells |
PT2242772E (en) | 2007-12-26 | 2015-02-09 | Biotest Ag | Immunoconjugates targeting cd138 and uses thereof |
GB0800277D0 (en) | 2008-01-08 | 2008-02-13 | Imagination Tech Ltd | Video motion compensation |
CN101918555B (en) * | 2008-01-11 | 2013-11-06 | 株式会社遗传科技 | Humanized anti-alpha9 integrin antibodies and the uses thereof |
MX2010007728A (en) | 2008-01-15 | 2010-12-21 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same. |
AU2009205995B2 (en) | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
EP2247619A1 (en) | 2008-01-24 | 2010-11-10 | Novo Nordisk A/S | Humanized anti-human nkg2a monoclonal antibody |
ES2848323T3 (en) | 2008-01-31 | 2021-08-06 | Inst Nat Sante Rech Med | Antibodies against human CD39 and their use to inhibit the activity of regulatory T cells |
CN101952454B (en) | 2008-02-08 | 2014-06-04 | 米迪缪尼有限公司 | Anti-IFNAR1 antibodies with reduced Fc ligand affinity |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
EP2260102A1 (en) | 2008-03-25 | 2010-12-15 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
WO2009119794A1 (en) | 2008-03-27 | 2009-10-01 | タカラバイオ株式会社 | Prophylactic/therapeutic agent for infectious disease |
US9908943B2 (en) | 2008-04-03 | 2018-03-06 | Vib Vzw | Single domain antibodies capable of modulating BACE activity |
WO2009121948A2 (en) | 2008-04-03 | 2009-10-08 | Vib Vzw | Single domain antibodies capable of modulating bace activity |
CN102056945A (en) | 2008-04-07 | 2011-05-11 | 埃博灵克斯股份有限公司 | Amino acid sequences directed against the Notch pathways and uses thereof |
ES2368700T3 (en) | 2008-04-11 | 2011-11-21 | Emergent Product Development Seattle, Llc | IMMUNOTHERAPEUTIC AGENT FOR CD37 AND COMBINATION WITH A BIFUNCTIONAL CHEMOTHERAPEUTIC AGENT OF THE SAME. |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
WO2009131256A1 (en) | 2008-04-24 | 2009-10-29 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
ES2458541T3 (en) | 2008-05-02 | 2014-05-06 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
MY159667A (en) | 2008-05-09 | 2017-01-13 | Abbvie Inc | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
JP6034023B2 (en) | 2008-05-16 | 2016-11-30 | アブリンクス エン.ヴェー. | Amino acid sequences directed to CXCR4 and other GPCRs and compounds containing the same |
CA2726131C (en) | 2008-05-29 | 2018-03-13 | Baoming Jiang | Expression and assembly of human group c rotavirus-like particles and uses thereof |
EP2304439A4 (en) | 2008-05-29 | 2012-07-04 | Nuclea Biotechnologies Llc | Anti-phospho-akt antibodies |
RU2010153578A (en) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION |
CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
ES2595362T3 (en) | 2008-06-16 | 2016-12-29 | Patrys Limited | LM antibodies, functional fragments, LM-1 target antigen and methods to prepare and use them |
CN110372792A (en) | 2008-06-25 | 2019-10-25 | 艾斯巴技术-诺华有限责任公司 | Inhibit the stabilization and soluble antibodies of VEGF |
RU2653753C1 (en) | 2008-06-25 | 2018-05-14 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
CN104004094B (en) * | 2008-06-25 | 2017-09-22 | 艾斯巴技术-诺华有限责任公司 | The humanization of the rabbit antibody carried out using universal antibody framework |
TW201014602A (en) | 2008-07-08 | 2010-04-16 | Abbott Lab | Prostaglandin E2 binding proteins and uses thereof |
RU2011104348A (en) | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AGAINST PROSTAGLANDINE E2 AND THEIR APPLICATION |
DK2982695T3 (en) | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | COMPOSITIONS CONCERNING ANTIBODIES AGAINST LINGO OR FRAGMENTS THEREOF |
JP5692746B2 (en) | 2008-08-07 | 2015-04-01 | 国立大学法人 長崎大学 | Treatment or prevention of systemic pain syndrome |
CA2735433C (en) | 2008-09-07 | 2016-02-16 | Glyconex Inc. | Anti-extended type i glycosphingolipid antibody, derivatives thereof and use |
US8937046B2 (en) | 2008-09-22 | 2015-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
DK2356153T3 (en) | 2008-10-01 | 2016-07-04 | Amgen Res (Munich) Gmbh | Bispecific single CHAIN PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES |
AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
WO2010040766A1 (en) | 2008-10-07 | 2010-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1) |
EP2350270B1 (en) | 2008-10-24 | 2018-03-07 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Human ebola virus species and compositions and methods thereof |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
EP2356251A1 (en) | 2008-11-07 | 2011-08-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Teneurin and cancer |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
SI2786762T1 (en) | 2008-12-19 | 2019-07-31 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US20120003235A1 (en) | 2008-12-31 | 2012-01-05 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
GB0900425D0 (en) | 2009-01-12 | 2009-02-11 | Ucb Pharma Sa | Biological products |
CA2749572A1 (en) | 2009-01-14 | 2010-07-22 | Iq Therapeutics Bv | Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins |
BRPI1007345A2 (en) | 2009-01-20 | 2019-04-16 | H. ZADEH Homayoun | mediated antibody bone regeneration |
KR20110110349A (en) | 2009-01-29 | 2011-10-06 | 아보트 러보러터리즈 | Il-1 binding proteins |
WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
EP2396035A4 (en) | 2009-02-12 | 2012-09-12 | Human Genome Sciences Inc | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
WO2010096486A1 (en) | 2009-02-17 | 2010-08-26 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
LT2398498T (en) | 2009-02-17 | 2019-01-10 | Ucb Biopharma Sprl | Antibody molecules having specificity for human ox40 |
GB0902916D0 (en) | 2009-02-20 | 2009-04-08 | Fusion Antibodies Ltd | Antibody therapy |
US8030026B2 (en) | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
EP2810652A3 (en) | 2009-03-05 | 2015-03-11 | AbbVie Inc. | IL-17 binding proteins |
WO2010100247A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
KR101667227B1 (en) | 2009-03-10 | 2016-10-18 | 가부시키가이샤 진 테크노 사이언스 | Generation, expression and characterization of the humanized k33n monoclonal antibody |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
EA024695B1 (en) * | 2009-03-16 | 2016-10-31 | Сефалон Острэйлиа Пти Лтд. | Humanised antibodies with anti-tumour activity |
EP3002296B1 (en) | 2009-03-17 | 2020-04-29 | Université d'Aix-Marseille | Btla antibodies and uses thereof |
EP2411412B1 (en) | 2009-03-24 | 2015-05-27 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against light and uses thereof |
EP2412825B8 (en) | 2009-03-24 | 2018-01-10 | Riken | Leukemia stem cell markers |
EP2417984B1 (en) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
NZ595461A (en) | 2009-04-10 | 2013-01-25 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
US8722860B2 (en) | 2009-04-16 | 2014-05-13 | Abbvie Biotherapeutics Inc. | Anti-TNF-α antibodies and their uses |
WO2010126066A1 (en) | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | Anti-il-3rα antibody for use in treatment of blood tumor |
US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
FR2945538B1 (en) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLARY FORM OF THE BETA-AMYLOID PEPTIDE. |
DK2438087T3 (en) | 2009-06-05 | 2017-08-28 | Ablynx Nv | TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS |
WO2010142603A1 (en) | 2009-06-08 | 2010-12-16 | Vib Vzw | Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation |
US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
CA2764545C (en) | 2009-06-15 | 2019-05-14 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Bace1 inhibitory antibodies |
MX346002B (en) | 2009-06-17 | 2017-03-01 | Abbvie Biotherapeutics Inc | Anti-vegf antibodies and their uses. |
WO2011005481A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
JP5871798B2 (en) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | How to stimulate liver regeneration |
EA022788B1 (en) | 2009-07-03 | 2016-03-31 | Бионор Иммуно Ас | Novel therapeutic and diagnostic means |
US8568719B2 (en) | 2009-08-13 | 2013-10-29 | Crucell Holland B.V. | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
WO2011020024A2 (en) | 2009-08-13 | 2011-02-17 | The Johns Hopkins University | Methods of modulating immune function |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
CN102002104A (en) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | Anti-VEGF monoclonal antibody and medicinal composition containing same |
EP3029070A1 (en) | 2009-08-29 | 2016-06-08 | AbbVie Inc. | Therapeutic dll4 binding proteins |
EP2473851A1 (en) | 2009-08-31 | 2012-07-11 | Abbott Biotherapeutics Corp. | Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
KR20120060877A (en) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | Dual variable domain immunoglobulins and uses thereof |
EP2480573A1 (en) | 2009-09-22 | 2012-08-01 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
AR078470A1 (en) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
PT2488551T (en) | 2009-10-16 | 2018-10-31 | Inst Nat Sante Rech Med | Monoclonal antibodies to progastrin and their uses |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
CN102781963B (en) | 2009-10-27 | 2018-02-16 | Ucb医药有限公司 | Functionalized modification NAv1.7 antibody |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
TW201122101A (en) | 2009-10-28 | 2011-07-01 | Facet Biotech Corp | Anti-EGFR antibodies and their uses |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
BR112012011463A2 (en) | 2009-10-30 | 2017-05-02 | Abbott Biotherapeutics Corp | use of nk cell immunoregulatory populations to predict the efficacy of anti-il-2r antibodies in multiple sclerosis patients. |
WO2011053707A1 (en) | 2009-10-31 | 2011-05-05 | Abbott Laboratories | Antibodies to receptor for advanced glycation end products (rage) and uses thereof |
CN102740885B (en) * | 2009-11-05 | 2015-04-01 | 梯瓦制药澳大利亚私人有限公司 | Treatment of cancer involving mutated kras or braf genes |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
CN102740888B (en) | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | IL-6 antibody and application thereof |
US8790887B2 (en) | 2009-12-04 | 2014-07-29 | Vib Vzw | Screening methods for compounds that modulate ARF-6 mediated endosomal redistribution |
SG181563A1 (en) | 2009-12-08 | 2012-07-30 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
EP2513148B1 (en) | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2 antibodies and their uses |
EA201270662A1 (en) | 2009-12-23 | 2013-01-30 | 4-Антибоди Аг | BINDING ELEMENTS FOR HUMAN CYTAMEGALOVIRUS |
US8900588B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
EP2542582A4 (en) | 2010-03-02 | 2013-12-04 | Abbvie Inc | Therapeutic dll4 binding proteins |
US9434716B2 (en) | 2011-03-01 | 2016-09-06 | Glaxo Group Limited | Antigen binding proteins |
EP2542578A1 (en) | 2010-03-05 | 2013-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Smoc1, tenascin-c and brain cancers |
JP5920929B2 (en) | 2010-03-11 | 2016-05-18 | ユセベ ファルマ ソシエテ アノニム | PD-1 antibody |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
PL2550294T3 (en) | 2010-03-24 | 2020-03-31 | Progastrine Et Cancers S.À R.L. | Prophylaxis of colorectal and gastrointestinal cancer |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
ES2717883T3 (en) | 2010-03-25 | 2019-06-26 | Ucb Biopharma Sprl | DVD-LG molecules stabilized with disulfide |
TWI653333B (en) | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | Cross-species specific PSMAxCD3 bispecific single chain antibody |
EP2558503B1 (en) | 2010-04-14 | 2015-12-09 | National Research Council of Canada | Compositions and methods for brain delivery of analgesic peptides |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
SG10201502967RA (en) | 2010-04-16 | 2015-05-28 | Biogen Ma Inc | Anti-vla-4 antibodies |
WO2011131611A1 (en) | 2010-04-19 | 2011-10-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
SI2571532T1 (en) | 2010-05-14 | 2017-10-30 | Abbvie Inc. | Il-1 binding proteins |
WO2011149461A1 (en) | 2010-05-27 | 2011-12-01 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
US20130089538A1 (en) | 2010-06-10 | 2013-04-11 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
NZ603581A (en) | 2010-06-19 | 2015-05-29 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
AU2011268780A1 (en) | 2010-06-25 | 2013-02-07 | Aston University | Glycoproteins having lipid mobilizing properties and therapeutic uses thereof |
WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
EA027835B1 (en) | 2010-07-09 | 2017-09-29 | Круселл Холланд Б.В. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use thereof |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
WO2012010696A1 (en) | 2010-07-23 | 2012-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for cancer management targeting co-029 |
CA2806157C (en) | 2010-07-26 | 2016-11-22 | Les Laboratoires Servier | Methods and compositions for liver cancer therapy |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
SG187173A1 (en) | 2010-07-30 | 2013-02-28 | Ac Immune Sa | Safe and functional humanized anti beta-amyloid antibody |
CA2807127C (en) | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
KR20130100118A (en) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | Dual variable domain immunoglobulins and uses therof |
EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US20130171159A1 (en) | 2010-09-10 | 2013-07-04 | Brian Arthur Hemmings | Phosphorylated twist1 and metastasis |
CA2813133C (en) | 2010-10-01 | 2023-10-31 | National Research Council Of Canada | Anti-ceacam6 antibodies and uses thereof |
UY33679A (en) | 2010-10-22 | 2012-03-30 | Esbatech | STABLE AND SOLUBLE ANTIBODIES |
WO2012055030A1 (en) | 2010-10-25 | 2012-05-03 | National Research Council Of Canada | Clostridium difficile-specific antibodies and uses thereof |
EP3404043B1 (en) | 2010-10-29 | 2022-10-26 | Perseus Proteomics Inc. | Anti-cdh3 antibody having high internalization capacity |
WO2012065937A1 (en) | 2010-11-15 | 2012-05-24 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Anti-fungal agents |
EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
WO2012071554A2 (en) | 2010-11-23 | 2012-05-31 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
US9249217B2 (en) | 2010-12-03 | 2016-02-02 | Secretary, DHHS | Bispecific EGFRvIII x CD3 antibody engaging molecules |
UA112170C2 (en) | 2010-12-10 | 2016-08-10 | Санофі | ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB |
WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
KR20140003467A (en) | 2010-12-20 | 2014-01-09 | 메디뮨 리미티드 | Anti-il-18 antibodies and their uses |
US20120275996A1 (en) | 2010-12-21 | 2012-11-01 | Abbott Laboratories | IL-1 Binding Proteins |
KR20130133247A (en) | 2010-12-21 | 2013-12-06 | 애브비 인코포레이티드 | Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use |
JP6147670B2 (en) | 2010-12-22 | 2017-06-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Modified antibodies with improved half-life |
US20130273062A1 (en) | 2010-12-22 | 2013-10-17 | Orega Biotech | Antibodies against human cd39 and use thereof |
US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
BR112013017951B1 (en) | 2011-01-14 | 2022-09-27 | UCB Biopharma SRL | NEUTRALIZATION ANTIBODY, ISOLATED DNA SEQUENCE, CLONING OR EXPRESSION VECTOR, PROCESS FOR PRODUCTION OF THE ANTIBODY, PHARMACEUTICAL COMPOSITION, USE OF ANTIBODY AND USE OF PHARMACEUTICAL COMPOSITION |
WO2012101125A1 (en) | 2011-01-24 | 2012-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific antibodies against human cxcl4 and uses thereof |
EP2668210B1 (en) | 2011-01-26 | 2020-06-17 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
WO2012110500A1 (en) | 2011-02-15 | 2012-08-23 | Vib Vzw | Means and methods for improvement of synaptic dysfunction disorders |
AR085302A1 (en) | 2011-02-24 | 2013-09-18 | Sanofi Sa | METHOD OF PRODUCTION OF STIRATED ANTIBODIES |
CN103402542B (en) | 2011-02-28 | 2017-05-03 | 独立行政法人国立循环器病研究中心 | Medicinal agent for inhibiting metastasis of malignant tumor |
WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
WO2012122528A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Bispecific three-chain antibody-like molecules |
US8722044B2 (en) | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
EP3235508B1 (en) | 2011-03-16 | 2020-12-30 | Sanofi | Compositions comprising a dual v region antibody-like protein |
EP3590969A1 (en) | 2011-03-31 | 2020-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
LT2699264T (en) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
SG194510A1 (en) | 2011-04-22 | 2013-12-30 | Emergent Product Dev Seattle | Prostate-specific membrane antigen binding proteins and related compositionsand methods |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
UA116189C2 (en) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
MX367097B (en) | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULATION FOR ANTI-a4ß7 ANTIBODY. |
US9127065B2 (en) | 2011-05-19 | 2015-09-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-human HER3 antibodies and uses thereof |
KR102030531B1 (en) | 2011-05-21 | 2019-10-10 | 마크로제닉스, 인크. | Deimmunized serum-binding domains and their use for extending serum half-life |
AR086543A1 (en) | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | GALECTIN-3 INHIBITORS AND METHODS OF USE OF THE SAME, PHARMACEUTICAL COMPOSITION |
AU2012264809B2 (en) | 2011-05-27 | 2017-05-04 | Ablynx Nv | Inhibition of bone resorption with RANKL binding peptides |
WO2012168259A1 (en) | 2011-06-06 | 2012-12-13 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
WO2012170740A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
HUE038509T2 (en) | 2011-06-10 | 2018-10-29 | Medimmune Ltd | Anti-pseudomonas psl binding molecules and uses thereof |
DK3006464T3 (en) | 2011-06-10 | 2018-09-17 | Canada Minister Nat Defence | ANTIRICIN ANTIBODIES AND APPLICATIONS THEREOF |
EP2723376B1 (en) | 2011-06-22 | 2018-12-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
CN103747803B (en) | 2011-06-22 | 2016-10-12 | 国家医疗保健研究所 | Anti-AXL antibodies and application thereof |
EP2543678A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
EP2543677A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
EP2543679A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
EP2734236A4 (en) | 2011-07-13 | 2015-04-15 | Abbvie Inc | Methods and compositions for treating asthma using anti-il-13 antibodies |
AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
CA2847245A1 (en) | 2011-09-09 | 2013-03-14 | Amgen Inc. | Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
MX2014002769A (en) | 2011-09-16 | 2014-06-11 | Ucb Pharma Sa | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile. |
EP2759551B1 (en) | 2011-09-21 | 2019-05-22 | Fujirebio Inc. | Antibodies binding to an affinity complex comprising 25oh vitamin d2 or d3 and an antibody thereto |
EP2758422A1 (en) | 2011-09-23 | 2014-07-30 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
JP6239517B2 (en) | 2011-10-10 | 2017-11-29 | メディミューン リミテッド | Treatment of rheumatoid arthritis |
MX2014004977A (en) | 2011-10-24 | 2014-09-11 | Abbvie Inc | Immunobinders directed against sclerostin. |
WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
ES2697674T3 (en) | 2011-11-01 | 2019-01-25 | Bionomics Inc | Procedures to block the growth of cancer stem cells |
AU2012332590B2 (en) | 2011-11-01 | 2016-10-20 | Bionomics, Inc. | Anti-GPR49 antibodies |
EP2773667A1 (en) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
JP2014533247A (en) | 2011-11-01 | 2014-12-11 | バイオノミクス インコーポレイテッド | Antibodies and methods of treating cancer |
ES2861435T3 (en) | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Specific compositions of isolated B7-H4 and methods of using them |
EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
EP2776022A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
WO2013070821A1 (en) | 2011-11-08 | 2013-05-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
PT2776466T (en) | 2011-11-11 | 2017-11-30 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
UA112203C2 (en) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin |
EP2599496A1 (en) | 2011-11-30 | 2013-06-05 | Kenta Biotech AG | Novel targets of Acinetobacter baumannii |
TWI640537B (en) | 2011-12-05 | 2018-11-11 | X 染色體有限公司 | Pdgf receptor beta binding polypeptides |
BR112014013694A2 (en) | 2011-12-08 | 2017-06-13 | Biotest Ag | method to treat a disease and kit |
WO2013093122A2 (en) | 2011-12-23 | 2013-06-27 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
WO2013092983A2 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
JP2015502397A (en) | 2011-12-23 | 2015-01-22 | ファイザー・インク | Engineered antibody constant regions for site-specific conjugation, and methods and uses therefor |
TW201333035A (en) | 2011-12-30 | 2013-08-16 | Abbvie Inc | Dual specific binding proteins directed against IL-13 and/or IL-17 |
EP2800583A1 (en) | 2012-01-02 | 2014-11-12 | Novartis AG | Cdcp1 and breast cancer |
US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
EP2804878B1 (en) | 2012-01-20 | 2018-08-22 | Genzyme Corporation | Anti-cxcr3 antibodies |
GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
MY176695A (en) | 2012-01-27 | 2020-08-19 | Abbvie Inc | Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration |
WO2013119990A2 (en) | 2012-02-10 | 2013-08-15 | Seattle Genetics, Inc. | Detection and treatment of cd30+ cancers |
PT2814844T (en) | 2012-02-15 | 2017-09-18 | Novo Nordisk As | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
SI2814842T1 (en) | 2012-02-15 | 2018-10-30 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
FR2987627B1 (en) | 2012-03-05 | 2016-03-18 | Splicos | USE OF RBM39 AS A BIOMARKER |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
TWI605060B (en) | 2012-03-28 | 2017-11-11 | 賽諾菲公司 | Antibodies to bradykinin b1 receptor ligands |
WO2013144240A1 (en) | 2012-03-29 | 2013-10-03 | Friedrich Miescher Institute For Biomedical Research | Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9980942B2 (en) | 2012-05-02 | 2018-05-29 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
EP3505537A1 (en) | 2012-05-07 | 2019-07-03 | Trustees of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
WO2013173364A2 (en) | 2012-05-14 | 2013-11-21 | Biogen Idec Ma Inc. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
JP6122948B2 (en) | 2012-05-15 | 2017-04-26 | モルフォテック, インコーポレイテッド | Methods for the treatment of gastric cancer |
WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
US20150174235A1 (en) | 2012-06-06 | 2015-06-25 | Bionor Immuno As | Vaccine |
US9676847B2 (en) | 2012-06-25 | 2017-06-13 | Orega Biotech | IL-17 antagonist antibodies |
WO2014001557A1 (en) | 2012-06-28 | 2014-01-03 | Ucb Pharma S.A. | A method for identifying compounds of therapeutic interest |
WO2014001482A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research | Treating diseases by modulating a specific isoform of mkl1 |
EP2870242A1 (en) | 2012-07-05 | 2015-05-13 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
MX2015000426A (en) | 2012-07-13 | 2015-07-14 | Univ Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody. |
US9334332B2 (en) | 2012-07-25 | 2016-05-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
KR20150043523A (en) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014033327A1 (en) | 2012-09-03 | 2014-03-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos for treating graft-versus-host disease |
WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
NO2760138T3 (en) | 2012-10-01 | 2018-08-04 | ||
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
KR102308915B1 (en) | 2012-10-15 | 2021-10-06 | 메디뮨 리미티드 | Antibodies to amyloid beta |
KR20150073211A (en) | 2012-10-24 | 2015-06-30 | 내셔날 리서치 카운실 오브 캐나다 | Anti-campylobacter jejuni antibodies and uses therefor |
CA2890263C (en) | 2012-11-01 | 2020-03-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
AU2013341711A1 (en) | 2012-11-12 | 2015-05-21 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
EP2733153A1 (en) | 2012-11-15 | 2014-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the preparation of immunoconjugates and uses thereof |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
JP2016505528A (en) | 2012-11-16 | 2016-02-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Picte-Spengler ligation for chemical modification of proteins |
WO2014079886A1 (en) | 2012-11-20 | 2014-05-30 | Sanofi | Anti-ceacam5 antibodies and uses thereof |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
WO2014083379A1 (en) | 2012-11-30 | 2014-06-05 | Institut Pasteur | Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
UA118255C2 (en) | 2012-12-07 | 2018-12-26 | Санофі | Compositions comprising anti-cd38 antibodies and lenalidomide |
WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
JP6359031B2 (en) | 2012-12-21 | 2018-07-18 | メディミューン,エルエルシー | Anti-H7CR antibody |
US9550986B2 (en) | 2012-12-21 | 2017-01-24 | Abbvie Inc. | High-throughput antibody humanization |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
EA201690004A1 (en) | 2012-12-27 | 2016-07-29 | Санофи | ANTIBODIES AGAINST LAMP1 AND CONJUGATES ANTIBODIES AND MEDICINES AND THEIR APPLICATION |
SI2949675T1 (en) | 2013-01-28 | 2021-08-31 | Evec Inc. | Humanized anti-hmgb1 antibody or antigen-binding fragment thereof |
EP2951199A4 (en) | 2013-01-31 | 2016-07-20 | Univ Jefferson | Fusion proteins for modulating regulatory and effector t cells |
PT2958943T (en) | 2013-02-20 | 2019-12-17 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
KR102241868B1 (en) | 2013-03-13 | 2021-04-20 | 사노피 | Compositions comprising anti-cd38 antibodies and carfilzomib |
JP2016512241A (en) | 2013-03-14 | 2016-04-25 | アボット・ラボラトリーズAbbott Laboratories | HCVNS3 recombinant antigen for improved antibody detection and mutants thereof |
JP6739329B2 (en) | 2013-03-14 | 2020-08-12 | アボット・ラボラトリーズAbbott Laboratories | HCV core lipid binding domain monoclonal antibody |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
EP2968526A4 (en) | 2013-03-14 | 2016-11-09 | Abbott Lab | Hcv antigen-antibody combination assay and methods and compositions for use therein |
EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
JP2016515524A (en) | 2013-03-15 | 2016-05-30 | アッヴィ バイオテクノロジー リミテッド | Anti-CD25 antibodies and their use |
EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
CN105143257B (en) | 2013-03-15 | 2020-10-27 | 艾伯维生物医疗股份有限公司 | FC variants |
WO2014144280A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17 |
KR102207859B1 (en) | 2013-03-15 | 2021-01-27 | 메모리얼 슬로안 케터링 캔서 센터 | High affinity anti-gd2 antibodies |
RU2015144033A (en) | 2013-03-15 | 2017-04-26 | Эббви Байотекнолоджи Лтд. | ANTIBODIES AGAINST CD25 AND THEIR APPLICATION |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
TWI654206B (en) | 2013-03-16 | 2019-03-21 | 諾華公司 | Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor |
TWI679019B (en) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | Anti-il-4/anti-il-13 bispecific antibody formulations |
SG10201913751RA (en) | 2013-05-06 | 2020-03-30 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
US10005839B2 (en) | 2013-05-17 | 2018-06-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antagonist of the BTLA/HVEM interaction for use in therapy |
AU2014268298B2 (en) | 2013-05-24 | 2019-01-17 | Medlmmune, Llc | Anti-B7-H5 antibodies and their uses |
SG11201509982UA (en) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
US9499628B2 (en) | 2013-06-14 | 2016-11-22 | Children's Hospital Medical Center | Method of boosting the immune response in neonates |
US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
JP6744212B2 (en) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Enzymatic binding of polypeptides |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
US20160178610A1 (en) | 2013-08-07 | 2016-06-23 | Friedrich Miescher Institute For Biomedical Research | New screening method for the treatment Friedreich's ataxia |
SG10201710013RA (en) | 2013-08-13 | 2018-01-30 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
TW201722994A (en) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and uses thereof |
GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
KR20160068742A (en) | 2013-09-04 | 2016-06-15 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | Dpp-4-targeting vaccine for treating diabetes |
WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
US9481729B2 (en) | 2013-09-11 | 2016-11-01 | The University Of Hong Kong | Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof |
ES2773306T3 (en) * | 2013-09-16 | 2020-07-10 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Bi or multispecific polypeptides binding to immune effector cell surface antigens and HBV antigens to treat HBV infections and associated states |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
CA2927968C (en) | 2013-10-25 | 2023-02-21 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
EP3733868A3 (en) | 2013-10-28 | 2021-01-13 | DOTS Technology Corp. | Allergen detection |
TN2016000142A1 (en) | 2013-10-31 | 2017-10-06 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers. |
CN105849125B (en) | 2013-11-07 | 2020-05-15 | 国家医疗保健研究所 | Neuregulin allosteric anti-HER 3 antibody |
US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
US9944694B2 (en) | 2013-12-13 | 2018-04-17 | Rijksuniversiteit Groningen | Antibodies against Staphylococcus aureus and uses therof |
WO2015095143A1 (en) | 2013-12-16 | 2015-06-25 | The University Of North Carolina At Chapel Hill | Depletion of plasmacytoid dendritic cells |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
JP6793902B2 (en) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | Adjustable chimeric antigen receptor |
PL3083680T3 (en) | 2013-12-20 | 2020-06-29 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
CA2935046C (en) | 2013-12-27 | 2021-04-13 | Osaka University | Vaccine targeting il-17a |
EP2893939A1 (en) | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
CN106029098A (en) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | Humanized RFB4 anti-CD22 antibody |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CA2942154C (en) | 2014-03-06 | 2023-06-27 | National Research Council Of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
US10106614B2 (en) | 2014-03-06 | 2018-10-23 | National Research Council Of Canada | Insulin-like growth factor 1 receptor-specific antibodies and uses thereof |
AU2014385801B2 (en) | 2014-03-06 | 2020-11-12 | National Research Council Of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
ES2857226T3 (en) | 2014-03-15 | 2021-09-28 | Novartis Ag | Regulable chimeric antigen receptor |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
CA2943242A1 (en) | 2014-03-21 | 2015-09-24 | X-Body, Inc. | Bi-specific antigen-binding polypeptides |
CN106536556B (en) | 2014-04-04 | 2020-02-07 | 生态学有限公司 | Humanized antibodies that bind LGR5 |
IL293603B2 (en) | 2014-04-07 | 2024-03-01 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
EP3131929B1 (en) | 2014-04-16 | 2022-06-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the prevention or the treatment of bleeding episodes |
WO2015164364A2 (en) | 2014-04-25 | 2015-10-29 | The Brigham And Women's Hospital, Inc. | Methods to manipulate alpha-fetoprotein (afp) |
LT3137114T (en) | 2014-04-30 | 2021-03-25 | Pfizer Inc. | Anti-ptk7 antibody-drug conjugates |
CN106413750B (en) | 2014-05-16 | 2022-04-29 | 免疫医疗有限责任公司 | Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties |
MA47849A (en) | 2014-05-28 | 2020-01-29 | Agenus Inc | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
EP3151830A4 (en) | 2014-06-06 | 2018-02-07 | Redwood Bioscience, Inc. | Anti-her2 antibody-maytansine conjugates and methods of use thereof |
WO2015189816A1 (en) | 2014-06-13 | 2015-12-17 | Friedrich Miescher Institute For Biomedical Research | New treatment against influenza virus |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
US10308935B2 (en) | 2014-06-23 | 2019-06-04 | Friedrich Miescher Institute For Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
US20170165261A1 (en) | 2014-07-01 | 2017-06-15 | Brian Arthur Hemmings | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
MY178347A (en) | 2014-07-17 | 2020-10-08 | Novo Nordisk As | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity |
CN112481283A (en) | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | Treatment of cancer using CD33 chimeric antigen receptor |
JP2017528433A (en) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | Low immunoenhancing dose of mTOR inhibitor and CAR combination |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
CN106687483B (en) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | Treatment of cancer using humanized anti-BCMA chimeric antigen receptors |
JP6721568B2 (en) | 2014-07-29 | 2020-07-15 | セレクティスCellectis | ROR1 (NTRKR1)-specific chimeric antigen receptor for cancer immunotherapy |
JP2017522893A (en) | 2014-07-31 | 2017-08-17 | セレクティスCellectis | ROR1-specific multi-chain chimeric antigen receptor |
US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
KR102626976B1 (en) | 2014-09-02 | 2024-01-18 | 이뮤노젠 아이엔씨 | Methods for formulating antibody drug conjugate compositions |
AU2015310897B2 (en) | 2014-09-04 | 2020-03-19 | Cellectis | Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
EA037647B1 (en) | 2014-09-05 | 2021-04-27 | Янссен Фармацевтика Нв | Cd123 binding agents and uses thereof |
WO2016043577A1 (en) | 2014-09-16 | 2016-03-24 | Academisch Medisch Centrum | Ig-like molecules binding to bmp4 |
DK3194443T3 (en) | 2014-09-17 | 2021-09-27 | Novartis Ag | TARGETING OF CYTOTOXIC CELLS WITH CHIMARY RECEPTORS IN CONNECTION WITH ADOPTIVE IMMUNTERAPHY |
US10080790B2 (en) | 2014-09-19 | 2018-09-25 | The Regents Of The University Of Michigan | Staphylococcus aureus materials and methods |
WO2016046768A1 (en) | 2014-09-24 | 2016-03-31 | Friedrich Miescher Institute For Biomedical Research | Lats and breast cancer |
WO2016054354A1 (en) * | 2014-10-02 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
CA3001724A1 (en) | 2014-10-10 | 2016-04-14 | National Research Council Of Canada | Anti-tau antibody and uses thereof |
EP3209769B1 (en) | 2014-10-24 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
CA2966035A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods of stimulating and expanding t cells |
SG11201703446RA (en) | 2014-10-31 | 2017-05-30 | Abbvie Biotherapeutics Inc | Anti-cs1 antibodies and antibody drug conjugates |
JP6879910B2 (en) | 2014-10-31 | 2021-06-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Modification of gene expression in CART cells and their use |
EP4183806A3 (en) | 2014-11-12 | 2023-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
US11072644B2 (en) | 2014-11-12 | 2021-07-27 | Allogene Therapeutics, Inc. | Inhibitory chimeric antigen receptors |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
EP3227341A1 (en) | 2014-12-02 | 2017-10-11 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
DK3029137T3 (en) | 2014-12-06 | 2019-04-08 | Gemoab Monoclonals Gmbh | GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF |
CA2970155A1 (en) | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
BR112017012377A2 (en) | 2014-12-09 | 2018-04-24 | Abbvie Inc | antibody-drug conjugates with cell-permeable bcl-x1 inhibitors |
CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
EP3229838B1 (en) | 2014-12-11 | 2020-09-09 | Pierre Fabre Medicament | Anti-c10orf54 antibodies and uses thereof |
CA2971517A1 (en) | 2014-12-19 | 2016-06-23 | Universite De Nantes | Anti il-34 antibodies |
US10941207B2 (en) | 2014-12-19 | 2021-03-09 | Chiome Bioscience, Inc | Fusion protein comprising three binding domains to 5T4 and CD3 |
EP3789039A1 (en) | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
MX2017009038A (en) | 2015-01-08 | 2017-10-25 | Biogen Ma Inc | Lingo-1 antagonists and uses for treatment of demyelinating disorders. |
CA2973978A1 (en) | 2015-01-14 | 2016-07-21 | The Brigham And Women's Hospital, Inc. | Treatment of cancer with anti-lap monoclonal antibodies |
ES2824167T3 (en) | 2015-01-23 | 2021-05-11 | Sanofi Sa | Anti-CD3 antibodies, anti-CD123 antibodies, and bispecific antibodies that specifically bind to CD3 and / or CD123 |
MX2017009181A (en) | 2015-01-26 | 2017-11-22 | Cellectis | ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY. |
AU2015380397B2 (en) | 2015-01-31 | 2021-10-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
US10266584B2 (en) | 2015-02-09 | 2019-04-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection |
WO2016139482A1 (en) | 2015-03-03 | 2016-09-09 | Kymab Limited | Antibodies, uses & methods |
EP3265483B1 (en) | 2015-03-06 | 2019-12-11 | CSL Behring Lengnau AG | Modified von willebrand factor having improved half-life |
EP3268125A4 (en) | 2015-03-13 | 2018-08-15 | President and Fellows of Harvard College | Determination of cells using amplification |
WO2016149368A1 (en) | 2015-03-17 | 2016-09-22 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
WO2016154585A1 (en) | 2015-03-26 | 2016-09-29 | Charles Sentman | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
EP3280455A1 (en) | 2015-04-07 | 2018-02-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Non-invasive imaging of tumor pd-l1 expression |
SI3280729T1 (en) | 2015-04-08 | 2022-09-30 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
PT3290441T (en) | 2015-04-28 | 2019-12-02 | Mitsubishi Tanabe Pharma Corp | Rgma binding protein and use thereof |
TW201702271A (en) | 2015-04-30 | 2017-01-16 | 哈佛大學校長及研究員協會 | Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders |
US20180140694A1 (en) | 2015-05-04 | 2018-05-24 | Bionor Immuno As | Dosage regimen for hiv vaccine |
WO2016179518A2 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
WO2016187068A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
CN107995913B (en) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | Compositions and methods for reprogramming TCRs using fusion proteins |
WO2016185035A1 (en) | 2015-05-20 | 2016-11-24 | Cellectis | Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy |
IL293719B2 (en) | 2015-05-21 | 2023-07-01 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
EA039951B1 (en) | 2015-05-27 | 2022-03-31 | Юсб Биофарма Спрл | Inhibitor of csf-1r activity for use in the treatment or prophylaxis of epilepsy or parkinson's disease and pharmaceutical composition thereof |
SG10201913500TA (en) | 2015-05-29 | 2020-03-30 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
HUE048284T2 (en) | 2015-05-29 | 2020-07-28 | Abbvie Inc | Anti-cd40 antibodies and uses thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
EP3313877B1 (en) | 2015-06-24 | 2020-06-03 | H. Hoffnabb-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
MA41669A1 (en) | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Antibodies binding to tau |
US10287343B2 (en) | 2015-07-06 | 2019-05-14 | Ucb Biopharma Sprl | Tau-binding antibodies |
EP3319990A1 (en) | 2015-07-07 | 2018-05-16 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Antibodies having specificity to myosin 18a and uses thereof |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
EP3331569A1 (en) | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
AU2016307050A1 (en) | 2015-08-11 | 2018-02-15 | Cellectis | Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation |
EP3340998B1 (en) | 2015-08-28 | 2023-01-11 | The Trustees of the University of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
EP3340995A4 (en) | 2015-08-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
EA201890630A1 (en) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION |
EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | Cd3 binding polypeptides |
WO2017060397A1 (en) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from melanoma metastases |
US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
CN108350068A (en) | 2015-10-27 | 2018-07-31 | Ucb生物制药私人有限公司 | Use the therapy of anti-IL-17A/F antibody |
US20180348224A1 (en) | 2015-10-28 | 2018-12-06 | Friedrich Miescher Institute For Biomedical Resear Ch | Tenascin-w and biliary tract cancers |
US11267875B2 (en) | 2015-10-28 | 2022-03-08 | Yale University | Humanized anti-DKK2 antibody and uses thereof |
TW201720459A (en) | 2015-11-02 | 2017-06-16 | 妮翠斯製藥公司 | Combination therapy of NTN1 neutralizing agent with drugs inhibiting epigenetic control |
CA3003759A1 (en) | 2015-11-03 | 2017-05-11 | Merck Patent Gmbh | Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof |
WO2017079419A1 (en) | 2015-11-05 | 2017-05-11 | The Regents Of The University Of California | Cells labelled with lipid conjugates and methods of use thereof |
IL258768B2 (en) | 2015-11-12 | 2023-11-01 | Siamab Therapeutics Inc | Glycan-interacting compounds and methods of use |
JP2019501139A (en) | 2015-11-25 | 2019-01-17 | イミュノジェン・インコーポレーテッド | Pharmaceutical formulations and uses thereof |
WO2017095808A1 (en) | 2015-11-30 | 2017-06-08 | Abbvie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
JP2019500327A (en) | 2015-11-30 | 2019-01-10 | アッヴィ・インコーポレイテッド | Anti-huLRRC15 antibody drug conjugate and method of use thereof |
KR20180100122A (en) | 2015-12-02 | 2018-09-07 | 주식회사 에스티사이언스 | Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor) |
AU2016365318B2 (en) | 2015-12-02 | 2024-04-18 | Board Of Regents, The University Of Texas System | Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
WO2017106372A1 (en) | 2015-12-15 | 2017-06-22 | Oncoimmune, Inc. | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
EP3184544A1 (en) | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Glycoprotein v inhibitors for use as coagulants |
EP3397965A1 (en) | 2015-12-31 | 2018-11-07 | Syncerus S.à R.l. | Compositions and methods for assessing the risk of cancer occurrence |
EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
GB201602413D0 (en) | 2016-02-10 | 2016-03-23 | Nascient Ltd | Method |
EP3419999B1 (en) | 2016-02-26 | 2021-08-04 | (INSERM) Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity for btla and uses thereof |
EP4299586A3 (en) | 2016-03-02 | 2024-04-03 | Idexx Laboratories, Inc. | Methods and compositions for the detection and diagnosis of renal disease and periodontal disease |
EP3423482A1 (en) | 2016-03-04 | 2019-01-09 | Novartis AG | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
KR20180119670A (en) | 2016-03-15 | 2018-11-02 | 아스트라제네카 아베 | Combinations of BACE inhibitors and antibody or antigen binding fragments for the treatment of diseases associated with the accumulation of amyloid beta |
LT3219727T (en) | 2016-03-17 | 2021-02-10 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
KR102392746B1 (en) | 2016-03-17 | 2022-04-29 | 누맙 이노베이션 아게 | Anti-TNFα-antibodies and functional fragments thereof |
WO2017158084A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF |
US10774140B2 (en) | 2016-03-17 | 2020-09-15 | Numab Therapeutics AG | Anti-TNFα-antibodies and functional fragments thereof |
RS61374B1 (en) | 2016-03-17 | 2021-02-26 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
US10745487B2 (en) | 2016-03-22 | 2020-08-18 | Bionomics Limited | Method of treating cancer by administering an anti-LGR5 monoclonal antibody |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
CA3018382A1 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
MX2018012615A (en) | 2016-04-15 | 2019-05-30 | Novartis Ag | Compositions and methods for selective protein expression. |
EP3448391A4 (en) | 2016-04-27 | 2019-12-18 | AbbVie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
CA3022494A1 (en) | 2016-05-01 | 2017-11-09 | Ucb Biopharma Sprl | Affinity engineered serum protein carrier binding domain |
WO2017194568A1 (en) | 2016-05-11 | 2017-11-16 | Sanofi | Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors |
KR20230028574A (en) | 2016-05-17 | 2023-02-28 | 애브비 바이오테라퓨틱스 인크. | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
CN109415441B (en) | 2016-05-24 | 2023-04-07 | 英斯梅德股份有限公司 | Antibodies and methods of making same |
US10875921B2 (en) | 2016-05-27 | 2020-12-29 | Abbvie Biotherapeutics Inc. | Anti-4-1BB antibodies and their uses |
JP2019523221A (en) | 2016-05-27 | 2019-08-22 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Anti-CD40 antibodies and uses thereof |
MX2018014387A (en) | 2016-05-27 | 2019-03-14 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof. |
US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
CN109563167A (en) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | Anti- B7-H3 antibody and antibody drug conjugates |
WO2017214335A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
CA3027103A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
MX2018015584A (en) | 2016-06-13 | 2019-09-18 | I Mab | Anti-pd-l1 antibodies and uses thereof. |
TWI784957B (en) | 2016-06-20 | 2022-12-01 | 英商克馬伯有限公司 | Immunocytokines |
AU2017281034B2 (en) | 2016-06-21 | 2024-03-14 | Teneobio, Inc. | CD3 binding antibodies |
KR20190039937A (en) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | Anti-ApoC3 antibodies and methods of use thereof |
CA3030841A1 (en) | 2016-07-14 | 2018-01-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
JP7219376B2 (en) | 2016-07-15 | 2023-02-08 | ノバルティス アーゲー | Treatment and prevention of cytokine release syndrome using chimeric antigen receptors in combination with kinase inhibitors |
TWI790206B (en) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 |
CN109477114A (en) | 2016-07-18 | 2019-03-15 | 赫利克斯生物药品公司 | The CAR immunocyte for carcinomebryonic antigen relevant cell adhesion molecule 6 for the treatment of cancer |
AU2017302668B9 (en) | 2016-07-28 | 2023-06-22 | Novartis Ag | Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
BR112019001693A2 (en) | 2016-07-29 | 2019-07-02 | Ct Hospitalier Universitaire Toulouse | antibodies targeting tumor-associated macrophages and their uses |
CA3032581A1 (en) | 2016-08-01 | 2018-02-08 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018038684A1 (en) | 2016-08-26 | 2018-03-01 | Agency For Science, Technology And Research | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof |
SG11201901716TA (en) | 2016-08-29 | 2019-03-28 | Psioxus Therapeutics Ltd | Adenovirus armed with bispecific t cell engager (bite) |
HUE051700T2 (en) | 2016-09-14 | 2021-03-29 | Abbvie Biotherapeutics Inc | Anti-pd-1 antibodies |
WO2018052503A1 (en) | 2016-09-14 | 2018-03-22 | Teneobio, Inc. | Cd3 binding antibodies |
WO2018050833A1 (en) | 2016-09-15 | 2018-03-22 | Ablynx Nv | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
JP7256116B2 (en) | 2016-09-19 | 2023-04-11 | アイ-エムエービー バイオファーマ (ハンジョウ) カンパニー リミテッド | ANTI-GM-CSF ANTIBODY AND USES THEREOF |
RU2759334C2 (en) | 2016-09-21 | 2021-11-12 | Нексткьюр, Инк. | Antibodies against siglec-15 and their application methods |
GB201616596D0 (en) | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
AR110676A1 (en) | 2016-10-07 | 2019-04-24 | Novartis Ag | TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS |
IL302917A (en) | 2016-10-07 | 2023-07-01 | Tcr2 Therapeutics Inc | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
TW202246349A (en) | 2016-10-11 | 2022-12-01 | 美商艾吉納斯公司 | Anti-lag-3 antibodies and methods of use thereof |
WO2018075474A1 (en) | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating central nervous system injury |
WO2018085359A1 (en) | 2016-11-02 | 2018-05-11 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
WO2018083538A1 (en) | 2016-11-07 | 2018-05-11 | Neuracle Scienc3 Co., Ltd. | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
US11773163B2 (en) | 2016-11-21 | 2023-10-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of metastases |
EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018098370A1 (en) | 2016-11-23 | 2018-05-31 | Immunoah Therapeutics, Inc. | 4-1bb binding proteins and uses thereof |
BR112019010602A2 (en) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | trispecific psma proteins and methods of use |
MX2019006043A (en) | 2016-11-23 | 2019-09-26 | Harpoon Therapeutics Inc | Prostate specific membrane antigen binding protein. |
MX2019006340A (en) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof. |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
KR20210157471A (en) | 2016-12-15 | 2021-12-28 | 애브비 바이오테라퓨틱스 인크. | Anti-ox40 antibodies and their uses |
GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
EP4215548A1 (en) | 2016-12-21 | 2023-07-26 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
WO2018119299A1 (en) | 2016-12-22 | 2018-06-28 | Sanofi | Humanized cxcr3 antibodies with depleting activity and methods of use thereof |
TW201840585A (en) | 2016-12-22 | 2018-11-16 | 法商賽諾菲公司 | Anti-human cxcr3 antibodies for treatment of vitiligo |
EA039433B1 (en) | 2017-01-05 | 2022-01-27 | Нетрис Фарма | Combined treatment with netrin-1 interfering drugs and immune checkpoint inhibitors drugs |
EP3565845A4 (en) | 2017-01-06 | 2020-10-07 | Biosion, Inc. | Erbb2 antibodies and uses therefore |
BR112019013238A2 (en) | 2017-01-20 | 2020-02-11 | Tayu Huaxia Biotech Medical Group Co., Ltd. | ANTI-PD-1 ANTIBODIES AND USES OF THE SAME |
CN109476755B (en) | 2017-01-24 | 2020-12-04 | 天境生物科技(上海)有限公司 | CD73 antibodies and uses thereof |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
CA3052095A1 (en) | 2017-01-30 | 2018-08-02 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |
EP3577134A1 (en) | 2017-01-31 | 2019-12-11 | Novartis AG | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
EP3354278A1 (en) | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
MA47442A (en) | 2017-02-07 | 2019-12-18 | Janssen Biotech Inc | ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLARTHRITIS |
US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
JP7304288B2 (en) | 2017-02-17 | 2023-07-06 | サノフイ | Multispecific binding molecules with specificity for dystroglycan and laminin-2 |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
WO2018158398A1 (en) | 2017-03-02 | 2018-09-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
MA47812A (en) | 2017-03-03 | 2021-04-14 | Seagen Inc | COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE |
CN110382544B (en) | 2017-03-16 | 2023-12-22 | 先天制药公司 | Compositions and methods for treating cancer |
TWI808963B (en) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | Treatment of lupus using humanized anti-cxcr5 antibodies |
US20200330590A1 (en) | 2017-03-27 | 2020-10-22 | Celgene Corporation | Methods and compositions for reduction of immunogenicity |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
BR112019017241A2 (en) | 2017-04-13 | 2020-04-14 | Agenus Inc | anti-cd137 antibodies and methods of using them |
BR112019021495A8 (en) | 2017-04-14 | 2023-05-02 | Inst Curie | AMHRII-BINDING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF LUNG CANCER |
CA3058282A1 (en) | 2017-04-14 | 2018-10-18 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating cancers |
CN110506056A (en) | 2017-04-21 | 2019-11-26 | 斯塔滕生物技术有限公司 | Anti- APOC3 antibody and its application method |
US20230140818A1 (en) | 2017-04-27 | 2023-05-04 | The University Of Hong Kong | Use of hcn inhibitors for treatment of cancer |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
EP3618863B1 (en) | 2017-05-01 | 2023-07-26 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
AU2018265261A1 (en) * | 2017-05-10 | 2019-12-05 | Inovio Pharmaceuticals, Inc. | Optimized nucleic acid antibody constructs |
KR102376863B1 (en) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | mesothelin binding protein |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
US11041011B2 (en) | 2017-05-12 | 2021-06-22 | Augusta University Research Institute, Inc. | Human alpha fetoprotein-specific murine T cell receptors and uses thereof |
JP7209936B2 (en) | 2017-05-12 | 2023-01-23 | ハープーン セラピューティクス,インク. | MSLN-targeting trispecific proteins and methods of use thereof |
KR20240042244A (en) | 2017-05-19 | 2024-04-01 | 신닥스 파마슈티컬스, 인크. | Combination therapies |
EP3630835A1 (en) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
EP3630834A1 (en) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
EP3409688A1 (en) | 2017-05-31 | 2018-12-05 | Tillotts Pharma Ag | Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof |
HUE063274T2 (en) | 2017-06-01 | 2024-01-28 | Akamis Bio Ltd | Oncolytic virus and method |
AR112069A1 (en) | 2017-06-02 | 2019-09-18 | Ablynx Nv | IMMUNOGLOBULINS THAT BIND AGGRECAN |
CN110997724A (en) | 2017-06-06 | 2020-04-10 | 斯特库伯株式会社 | Methods of treating cancer using antibodies and molecules that bind BTN1A1 or BTN1A 1-ligands |
US20210079057A1 (en) | 2017-06-13 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
AU2018288803A1 (en) | 2017-06-20 | 2020-02-06 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
CN110831965B (en) | 2017-06-21 | 2023-03-07 | 吉利德科学公司 | Multispecific antibodies targeting HIV GP120 and CD3 |
CA3068672A1 (en) | 2017-06-28 | 2019-01-03 | The Rockefeller University | Anti-mertk agonistic antibody-drug conjugates and uses thereof |
US20190048073A1 (en) | 2017-07-20 | 2019-02-14 | Pfizer Inc. | Anti-gd3 antibodies and antibody-drug conjugates |
US11174322B2 (en) | 2017-07-24 | 2021-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat HCMV related diseases |
AU2018306436A1 (en) | 2017-07-27 | 2020-02-13 | Nomocan Pharmaceuticals Llc | Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer |
JP6889328B2 (en) * | 2017-07-31 | 2021-06-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Humanization method based on three-dimensional structure |
AU2018323470A1 (en) | 2017-08-28 | 2020-03-19 | Angiex, Inc. | Anti-TM4SF1 antibodies and methods of using same |
EP3679070A1 (en) | 2017-09-07 | 2020-07-15 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
EP3456739A1 (en) | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Use of anti-tnfalpha antibodies for treating wounds |
EP3459529A1 (en) | 2017-09-20 | 2019-03-27 | Tillotts Pharma Ag | Preparation of sustained release solid dosage forms comprising antibodies by spray drying |
EP3459527B1 (en) | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
ES2938609T3 (en) | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparation of Solid Dosage Forms Comprising Antibodies by Solution/Suspension Layering |
MX2020003219A (en) | 2017-09-21 | 2020-07-20 | Imcheck Therapeutics Sas | Antibodies having specificity for btn2 and uses thereof. |
CA3078460A1 (en) | 2017-10-04 | 2019-04-11 | Opko Pharmaceuticals, Llc | Articles and methods directed to personalized therapy of cancer |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
JP7356727B2 (en) | 2017-10-12 | 2023-10-05 | 慶應義塾 | Anti-AQP3 monoclonal antibody that specifically binds to the extracellular domain of aquaporin 3 (AQP3), and use thereof |
CR20200195A (en) | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | B cell maturation antigen binding proteins |
KR102569133B1 (en) | 2017-10-13 | 2023-08-21 | 하푼 테라퓨틱스, 인크. | Trispecific proteins and methods of use |
CA3080103A1 (en) | 2017-10-31 | 2019-05-09 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
WO2019089594A1 (en) | 2017-10-31 | 2019-05-09 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
WO2019099440A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
WO2019102435A1 (en) | 2017-11-27 | 2019-05-31 | Euro-Celtique S.A. | Humanized antibodies targeting human tissue factor |
KR20200104364A (en) | 2017-12-27 | 2020-09-03 | 테네오바이오, 인코포레이티드 | CD3-delta/epsilon heterodimer specific antibody |
GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
AU2019225393A1 (en) | 2018-02-23 | 2020-08-20 | Cartherics Pty. Ltd. | T cell disease treatment targeting TAG-72 |
US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
GB201804701D0 (en) | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
JP2021521273A (en) | 2018-04-12 | 2021-08-26 | メディアファーマ エス.アール.エル. | LGALS3BP antibody-drug conjugate and its use for cancer treatment |
WO2019207159A1 (en) | 2018-04-27 | 2019-10-31 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019222130A1 (en) | 2018-05-15 | 2019-11-21 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and flt3 inhibitors |
EP3802609A2 (en) | 2018-05-24 | 2021-04-14 | Janssen Biotech, Inc. | Psma binding agents and uses thereof |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
AU2019289176A1 (en) | 2018-06-18 | 2020-12-24 | Oxford University Innovation Limited | Gremlin-1 antagonist for the prevention and treatment of cancer |
EA202092518A1 (en) | 2018-06-18 | 2021-08-23 | Иннейт Фарма | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
WO2019244107A1 (en) | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
EA202190092A1 (en) | 2018-06-21 | 2021-05-18 | Юманити Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS |
EP3814369A1 (en) | 2018-06-29 | 2021-05-05 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Tweak-receptor agonists for use in combination with immunotherapy of a cancer |
WO2020003210A1 (en) | 2018-06-29 | 2020-01-02 | Kangwon National University University-Industry Cooperation Foundation | Anti-l1cam antibodies and uses thereof |
EP3821908A4 (en) | 2018-07-10 | 2022-03-30 | Mitsubishi Tanabe Pharma Corporation | Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized |
BR112021000934A2 (en) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receiver for sight |
SG11202101811VA (en) | 2018-08-30 | 2021-03-30 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using fusion proteins |
EP4268831A2 (en) | 2018-09-12 | 2023-11-01 | Fred Hutchinson Cancer Center | Reducing cd33 expression to selectively protect therapeutic cells |
WO2020061210A1 (en) | 2018-09-18 | 2020-03-26 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
JP7425049B2 (en) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | DLL3 binding protein and method of use |
US20220047633A1 (en) | 2018-09-28 | 2022-02-17 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
AU2019349958A1 (en) | 2018-09-28 | 2021-05-06 | Kyowa Kirin Co., Ltd. | IL-36 antibodies and uses thereof |
CN112969503A (en) | 2018-10-03 | 2021-06-15 | 斯塔滕生物技术有限公司 | Antibodies specific for human and cynomolgus macaques APOC3 and methods of use thereof |
JP2022504839A (en) | 2018-10-10 | 2022-01-13 | ティロス・セラピューティクス・インコーポレイテッド | Anti-LAP antibody mutants and their use |
CA3116091A1 (en) | 2018-10-16 | 2020-04-23 | UCB Biopharma SRL | Method for the treatment of myasthenia gravis |
GB201817309D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
GB201817311D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
EP3877413A1 (en) | 2018-11-06 | 2021-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
US20220026445A1 (en) | 2018-12-07 | 2022-01-27 | Georgia Tech Research Corporation | Antibodies that bind to natively folded myocilin |
WO2020123662A2 (en) | 2018-12-11 | 2020-06-18 | AdMIRx Inc. | Fusion protein constructs for complement associated disease |
JP2022516408A (en) | 2018-12-14 | 2022-02-28 | インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) | Isolated MHC-derived human peptides and their use for stimulating and activating the inhibitory function of CD8 + CD45RCrowTreg. |
WO2020128927A1 (en) | 2018-12-20 | 2020-06-25 | Kyowa Kirin Co., Ltd. | Fn14 antibodies and uses thereof |
GB201900732D0 (en) | 2019-01-18 | 2019-03-06 | Ucb Biopharma Sprl | Antibodies |
CA3127776A1 (en) | 2019-01-30 | 2020-08-06 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
WO2020157305A1 (en) | 2019-01-31 | 2020-08-06 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
AU2020218446B2 (en) | 2019-02-04 | 2023-05-25 | National University Corporation Ehime University | "CAR LIBRARY AND scFv MANUFACTURING METHOD |
WO2020169472A2 (en) | 2019-02-18 | 2020-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing phenotypic changes in macrophages |
EP3927371A1 (en) | 2019-02-22 | 2021-12-29 | Novartis AG | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
WO2020168555A1 (en) | 2019-02-22 | 2020-08-27 | 武汉友芝友生物制药有限公司 | Cd3 antigen binding fragment and application thereof |
EP3929212A4 (en) | 2019-02-22 | 2022-11-23 | Wuhan Yzy Biopharma Co., Ltd. | Modified fc fragment, antibody comprising same, and application thereof |
MA55080A (en) | 2019-02-26 | 2022-01-05 | Inspirna Inc | HIGH AFFINITY ANTI-MERTK ANTIBODIES AND ASSOCIATED USES |
CA3131953A1 (en) | 2019-03-01 | 2020-09-10 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
WO2020188086A1 (en) | 2019-03-20 | 2020-09-24 | Imcheck Therapeutics Sas | Antibodies having specificity for btn2 and uses thereof |
US20220177558A1 (en) | 2019-03-25 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
US20210277131A1 (en) | 2019-03-26 | 2021-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT EMPLOYING ANTI-IL-l3R ANTIBODY OR BINDING FRAGMENT THEREOF |
WO2020198731A2 (en) | 2019-03-28 | 2020-10-01 | Danisco Us Inc | Engineered antibodies |
WO2020213084A1 (en) | 2019-04-17 | 2020-10-22 | Keio University | Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof |
TW202100559A (en) | 2019-05-21 | 2021-01-01 | 瑞士商諾華公司 | Cd19 binding molecules and uses thereof |
US20230071196A1 (en) | 2019-05-21 | 2023-03-09 | Novartis Ag | Variant cd58 domains and uses thereof |
JP2022534020A (en) | 2019-05-23 | 2022-07-27 | ヤンセン バイオテツク,インコーポレーテツド | Methods of treating inflammatory bowel disease with combination therapy of antibodies against IL-23 and TNF-alpha |
JP2022537931A (en) | 2019-06-14 | 2022-08-31 | テネオバイオ, インコーポレイテッド | A multispecific heavy chain antibody that binds to CD22 and CD3 |
SG11202111943UA (en) | 2019-07-02 | 2021-11-29 | Hutchinson Fred Cancer Res | Recombinant ad35 vectors and related gene therapy improvements |
CN113968910A (en) | 2019-07-11 | 2022-01-25 | 武汉友芝友生物制药有限公司 | Tetravalent symmetric bispecific antibodies |
CA3146341A1 (en) | 2019-07-30 | 2021-02-04 | Aaron L. Kurtzman | Bispecific anti lrrc15 and cd3epsilun antibudies |
WO2021023624A1 (en) | 2019-08-02 | 2021-02-11 | Orega Biotech | Novel il-17b antibodies |
US20220242962A1 (en) | 2019-08-12 | 2022-08-04 | Aptevo Research And Development Llc | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US11680098B2 (en) | 2019-08-30 | 2023-06-20 | Agenus Inc. | Antibodies that specifically bind human CD96 |
JP2022547850A (en) | 2019-09-03 | 2022-11-16 | バイオ - テラ ソリューションズ、リミテッド | Anti-TIGIT immune inhibitor and application |
JP2022549504A (en) | 2019-09-26 | 2022-11-25 | エスティーキューブ アンド カンパニー | Antibodies specific for glycosylated CTLA-4 and methods of use thereof |
US20220324962A1 (en) | 2019-09-27 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance antibodies and uses thereof |
WO2021058729A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof |
WO2021072277A1 (en) | 2019-10-09 | 2021-04-15 | Stcube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
EP3825330A1 (en) | 2019-11-19 | 2021-05-26 | International-Drug-Development-Biotech | Anti-cd117 antibodies and methods of use thereof |
EP4061944A1 (en) | 2019-11-22 | 2022-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
GB201917480D0 (en) | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
WO2021116119A1 (en) | 2019-12-09 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
WO2021116277A1 (en) | 2019-12-10 | 2021-06-17 | Institut Pasteur | New antibody blocking human fcgriiia and fcgriiib |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
AR120898A1 (en) | 2019-12-26 | 2022-03-30 | Univ Osaka | AGENT TO TREAT OR PREVENT ACUTE NEUROMYELITIS OPTICA |
TW202138388A (en) | 2019-12-30 | 2021-10-16 | 美商西根公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
US20230090552A1 (en) | 2020-01-08 | 2023-03-23 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
JPWO2021145432A1 (en) | 2020-01-15 | 2021-07-22 | ||
JPWO2021145435A1 (en) | 2020-01-15 | 2021-07-22 | ||
GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
CA3167027A1 (en) | 2020-02-05 | 2021-08-12 | Larimar Therapeutics, Inc. | Tat peptide binding proteins and uses thereof |
EP4103608A1 (en) | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd137 |
US20230096030A1 (en) | 2020-02-13 | 2023-03-30 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd7 |
US20230125234A1 (en) | 2020-02-13 | 2023-04-27 | UCB Biopharma SRL | Anti cd44-ctla4 bispecific antibodies |
EP4103611B1 (en) | 2020-02-13 | 2024-03-27 | UCB Biopharma SRL | Bispecific antibodies binding hvem and cd9 |
US20230151109A1 (en) | 2020-02-13 | 2023-05-18 | UCB Biopharma SRL | Bispecific antibodies against cd9 |
AU2021224851A1 (en) | 2020-02-21 | 2022-09-15 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
IL295590A (en) | 2020-02-28 | 2022-10-01 | Genzyme Corp | Modified binding polypeptides for optimized drug conjugation |
WO2021175954A1 (en) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Antibodies having specificity for btnl8 and uses thereof |
CN115315446A (en) | 2020-03-06 | 2022-11-08 | Go医疗股份有限公司 | anti-sugar-CD 44 antibodies and uses thereof |
IL296241A (en) | 2020-03-10 | 2022-11-01 | Massachusetts Inst Technology | Compositions and methods for immunotherapy of npm1c-positive cancer |
US20230203191A1 (en) | 2020-03-30 | 2023-06-29 | Danisco Us Inc | Engineered antibodies |
WO2021197340A1 (en) | 2020-03-31 | 2021-10-07 | 百奥泰生物制药股份有限公司 | Antibody and fusion protein for treating coronaviruses and use thereof |
US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
CN115427083A (en) | 2020-04-24 | 2022-12-02 | 赛诺菲 | Antitumor combination comprising anti-CEACAM 5 antibody conjugate and cetuximab |
EP4138926A1 (en) | 2020-04-24 | 2023-03-01 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox |
WO2021214222A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil |
AU2021261553A1 (en) | 2020-04-24 | 2023-01-05 | Sanofi | Antitumor combinations containing anti-CEACAM5 antibody conjugates and FOLFIFI |
CN113637082A (en) | 2020-04-27 | 2021-11-12 | 启愈生物技术(上海)有限公司 | Bispecific antibody targeting human claudin and human PDL1 protein and application thereof |
BR112022021690A2 (en) | 2020-04-29 | 2022-12-20 | Teneobio Inc | MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS |
EP4149558A1 (en) | 2020-05-12 | 2023-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas |
EP3915641A1 (en) | 2020-05-27 | 2021-12-01 | International-Drug-Development-Biotech | Anti-cd5 antibodies and methods of use thereof |
EP4165169A1 (en) | 2020-06-11 | 2023-04-19 | Novartis AG | Zbtb32 inhibitors and uses thereof |
EP4183416A1 (en) | 2020-07-17 | 2023-05-24 | Mitsubishi Tanabe Pharma Corporation | Agent for preventing or treating muscular disease |
WO2022028608A1 (en) | 2020-08-07 | 2022-02-10 | 百奥泰生物制药股份有限公司 | Anti pd-l1 antibody and application thereof |
BR112023001733A2 (en) | 2020-09-04 | 2023-03-28 | Merck Patent Gmbh | ANTI-CEACAM5 AND CONJUGATE ANTIBODIES AND THEIR USES |
JP2023544839A (en) | 2020-10-07 | 2023-10-25 | ゾエティス・サービシーズ・エルエルシー | Anti-NGF antibody and its usage method |
EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
EP4229081A1 (en) | 2020-10-15 | 2023-08-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
EP4229086A1 (en) | 2020-10-15 | 2023-08-23 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
CA3191224A1 (en) | 2020-10-16 | 2022-04-21 | Shenda GU | Multispecific binding compounds that bind to pd-l1 |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
JP2023550596A (en) | 2020-11-02 | 2023-12-04 | ユーシービー バイオファルマ エスアールエル | Use of anti-TREM1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
US20240067728A1 (en) | 2020-11-06 | 2024-02-29 | Bio-Thera Solutions, Ltd. | Bispecific antibody and use thereof |
EP4240494A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
MX2023005609A (en) | 2020-11-13 | 2023-05-29 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells. |
MX2023006426A (en) | 2020-12-01 | 2023-07-17 | Aptevo Res And Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies. |
MX2023006650A (en) | 2020-12-07 | 2023-06-21 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations. |
BR112023008265A2 (en) | 2020-12-07 | 2024-02-06 | UCB Biopharma SRL | ANTIBODIES AGAINST INTERLEUKIN-22 |
TW202237639A (en) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
TW202237638A (en) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
US20240092892A1 (en) | 2020-12-30 | 2024-03-21 | Bio-Thera Solutions, Ltd. | Anti-cldn18.2 antibody, and preparation method therefor and use thereof |
WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
KR20230146521A (en) | 2021-01-13 | 2023-10-19 | 메모리얼 슬로안 케터링 캔서 센터 | Antibody-pyrrolobenzodiazepine derivative conjugate |
US20240115721A1 (en) | 2021-01-13 | 2024-04-11 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
WO2022159575A1 (en) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
UY39610A (en) | 2021-01-20 | 2022-08-31 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
JP2024508157A (en) | 2021-03-04 | 2024-02-22 | センター ナショナル デ ラ レシェルシェ サイエンティフィーク | Use of periostin antibodies to treat inflammation, fibrosis and lung diseases |
EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
CA3208011A1 (en) | 2021-03-17 | 2022-09-22 | Sarah Harris | Methods of treating atopic dermatitis with anti il-13 antibodies |
AU2022246275A1 (en) | 2021-03-26 | 2023-11-09 | Janssen Biotech, Inc. | Humanized antibodies against paired helical filament tau and uses thereof |
EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
AU2022268545A1 (en) | 2021-05-03 | 2023-11-02 | UCB Biopharma SRL | Antibodies |
US20220372168A1 (en) | 2021-05-04 | 2022-11-24 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
EP4334354A1 (en) | 2021-05-06 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
IL309349A (en) | 2021-06-14 | 2024-02-01 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
AR126161A1 (en) | 2021-06-17 | 2023-09-27 | Boehringer Lngelheim Int Gmbh | NOVEL TRISPECIFIC BINDING MOLECULES |
US20230174651A1 (en) | 2021-06-23 | 2023-06-08 | Janssen Biotech, Inc. | Materials and methods for hinge regions in functional exogenous receptors |
IL309405A (en) | 2021-06-29 | 2024-02-01 | Seagen Inc | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
IL310437A (en) | 2021-07-29 | 2024-03-01 | Inst Nat Sante Rech Med | Humanized anti-human βig-h3 protein and uses thereof |
CN117642421A (en) | 2021-07-29 | 2024-03-01 | 武田药品工业株式会社 | Engineered immune cells specifically targeting mesothelin and uses thereof |
WO2023014863A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
CA3227511A1 (en) | 2021-08-06 | 2023-02-09 | Lætitia LINARES | Methods for the treatment of cancer |
WO2023019200A1 (en) | 2021-08-11 | 2023-02-16 | Viela Bio, Inc. | Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
TW202325733A (en) | 2021-09-03 | 2023-07-01 | 美商Go治療公司 | Anti-glyco-lamp1 antibodies and their uses |
CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
WO2023048650A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
WO2023048651A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Method for treatment of moderate to severe atoptic dematitis |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
GB202115122D0 (en) | 2021-10-21 | 2021-12-08 | Dualyx Nv | Binding molecules targeting IL-2 receptor |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
TW202333784A (en) | 2021-10-29 | 2023-09-01 | 新加坡商亞獅康私人有限公司 | Anti-il-13r antibody formulation |
TW202333797A (en) | 2021-11-05 | 2023-09-01 | 法商賽諾菲公司 | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies |
WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
WO2023131901A1 (en) | 2022-01-07 | 2023-07-13 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
WO2023140780A1 (en) | 2022-01-24 | 2023-07-27 | Aslan Pharmaceuticals Pte Ltd. | Method of treating inflammatory disease |
TW202337905A (en) | 2022-02-23 | 2023-10-01 | 新加坡商亞獅康私人有限公司 | Glycosylated form of anti-il13r antibody |
WO2023170240A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
WO2023172968A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
TW202345899A (en) | 2022-03-11 | 2023-12-01 | 比利時商健生藥品公司 | Multispecific antibodies and uses thereof |
WO2023170291A1 (en) | 2022-03-11 | 2023-09-14 | Janssen Pharmaceutica Nv | Multispecific antibodies and uses thereof |
WO2023170290A1 (en) | 2022-03-11 | 2023-09-14 | Janssen Pharmaceutica Nv | Multispecific antibodies and uses thereof |
EP4245772A1 (en) | 2022-03-18 | 2023-09-20 | Netris Pharma | Anti-netrin-1 antibody to treat liver inflammation |
EP4249509A1 (en) | 2022-03-22 | 2023-09-27 | Netris Pharma | Anti-netrin-1 antibody against arthritis-associated pain |
WO2023186968A1 (en) | 2022-03-29 | 2023-10-05 | Netris Pharma | Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor |
GB202205200D0 (en) | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
WO2023239803A1 (en) | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
WO2023240287A1 (en) | 2022-06-10 | 2023-12-14 | Bioentre Llc | Combinations of ctla4 binding proteins and methods of treating cancer |
WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
GB202210679D0 (en) | 2022-07-21 | 2022-09-07 | Dualyx Nv | Binding molecules targeting il-12rb2 |
GB202210680D0 (en) | 2022-07-21 | 2022-09-07 | Dualyx Nv | Binding molecules targeting il-35r |
WO2024018426A1 (en) | 2022-07-22 | 2024-01-25 | Janssen Biotech, Inc. | Enhanced transfer of genetic instructions to effector immune cells |
WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
WO2024043837A1 (en) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
WO2024050354A1 (en) | 2022-08-31 | 2024-03-07 | Washington University | Alphavirus antigen binding antibodies and uses thereof |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
WO2024054157A1 (en) | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Treatment for sleep loss or sleep disturbance in patients with dermatitis |
WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
WO2024056861A1 (en) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Multispecific antigen binding proteins for stimulating nk cells and use thereof |
WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
WO2024062082A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
GB202214132D0 (en) | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
WO2024068996A1 (en) | 2022-09-30 | 2024-04-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
EP4353253A1 (en) | 2022-10-10 | 2024-04-17 | Charité - Universitätsmedizin Berlin | Purification of tcr-modified t cells using tcr-specific car-nk cells |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695459A (en) * | 1984-12-26 | 1987-09-22 | The Board Of Trustees Of Leland Stanford Junior University | Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells |
EP0328404A1 (en) * | 1988-02-12 | 1989-08-16 | Btg International Limited | Modified antibodies |
EP0365209A2 (en) * | 1988-10-17 | 1990-04-25 | Becton, Dickinson and Company | Anti-leu 3A amino acid sequence |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4348376A (en) * | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
AU625613B2 (en) * | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
CA2018248A1 (en) * | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
US5062934A (en) * | 1989-12-18 | 1991-11-05 | Oronzio Denora S.A. | Method and apparatus for cathodic protection |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
GB9019812D0 (en) * | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
GB9021679D0 (en) * | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
JP3854306B2 (en) * | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Humanized and chimeric monoclonal antibodies |
DK0610201T4 (en) * | 1991-03-18 | 2008-02-04 | Centocor Inc | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
JPH06202412A (en) * | 1992-12-26 | 1994-07-22 | Canon Inc | Image forming device |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5535089A (en) * | 1994-10-17 | 1996-07-09 | Jing Mei Industrial Holdings, Ltd. | Ionizer |
-
1989
- 1989-12-21 GB GB898928874A patent/GB8928874D0/en active Pending
-
1990
- 1990-12-21 AT AT94202090T patent/ATE208794T1/en not_active IP Right Cessation
- 1990-12-21 EP EP94104042A patent/EP0620276A1/en not_active Withdrawn
- 1990-12-21 WO PCT/GB1990/002018 patent/WO1991009968A1/en active IP Right Grant
- 1990-12-21 WO PCT/GB1990/002015 patent/WO1991009966A1/en active IP Right Grant
- 1990-12-21 DE DE69020544T patent/DE69020544T2/en not_active Expired - Lifetime
- 1990-12-21 AU AU69740/91A patent/AU646009B2/en not_active Expired
- 1990-12-21 DK DK91901433.2T patent/DK0460167T3/en active
- 1990-12-21 EP EP91901835A patent/EP0460178B1/en not_active Expired - Lifetime
- 1990-12-21 WO PCT/GB1990/002017 patent/WO1991009967A1/en not_active Application Discontinuation
- 1990-12-21 JP JP50186591A patent/JP3242913B2/en not_active Expired - Lifetime
- 1990-12-21 ES ES91901433T patent/ES2079638T3/en not_active Expired - Lifetime
- 1990-12-21 RO RO148281A patent/RO114232B1/en unknown
- 1990-12-21 ES ES91901559T patent/ES2074701T3/en not_active Expired - Lifetime
- 1990-12-21 JP JP50210791A patent/JP3452062B2/en not_active Expired - Lifetime
- 1990-12-21 AT AT91901559T patent/ATE124459T1/en not_active IP Right Cessation
- 1990-12-21 AT AT91901433T patent/ATE129017T1/en not_active IP Right Cessation
- 1990-12-21 ES ES94202090T patent/ES2165864T3/en not_active Expired - Lifetime
- 1990-12-21 RO RO148283A patent/RO114980B1/en unknown
- 1990-12-21 AT AT91901835T patent/ATE159299T1/en not_active IP Right Cessation
- 1990-12-21 AU AU70330/91A patent/AU649645B2/en not_active Expired
- 1990-12-21 DK DK91901559.4T patent/DK0460171T3/en active
- 1990-12-21 HU HU752/91A patent/HU217693B/en unknown
- 1990-12-21 EP EP91901433A patent/EP0460167B1/en not_active Revoked
- 1990-12-21 EP EP94202090A patent/EP0626390B1/en not_active Revoked
- 1990-12-21 DE DE69033857T patent/DE69033857T2/en not_active Revoked
- 1990-12-21 CA CA002046904A patent/CA2046904C/en not_active Expired - Lifetime
- 1990-12-21 AU AU70486/91A patent/AU631481B2/en not_active Expired
- 1990-12-21 DK DK94202090T patent/DK0626390T3/en active
- 1990-12-21 KR KR1019910700949A patent/KR100197956B1/en not_active IP Right Cessation
- 1990-12-21 EP EP91901559A patent/EP0460171B1/en not_active Expired - Lifetime
- 1990-12-21 DE DE69022982T patent/DE69022982T2/en not_active Revoked
- 1990-12-21 JP JP3501864A patent/JPH04505398A/en active Pending
- 1990-12-21 RO RO148282A patent/RO114298B1/en unknown
- 1990-12-21 KR KR1019910700944A patent/KR100191152B1/en not_active IP Right Cessation
- 1990-12-21 DK DK91901835.8T patent/DK0460178T3/en active
- 1990-12-21 HU HU912751A patent/HUT60786A/en unknown
- 1990-12-21 BR BR909007197A patent/BR9007197A/en unknown
- 1990-12-21 RU SU5001870A patent/RU2112037C1/en active
- 1990-12-21 HU HU912734A patent/HUT58372A/en unknown
- 1990-12-21 DE DE69031591T patent/DE69031591T2/en not_active Expired - Lifetime
- 1990-12-21 CA CA002050479A patent/CA2050479C/en not_active Expired - Lifetime
- 1990-12-21 ES ES91901835T patent/ES2112270T3/en not_active Expired - Lifetime
- 1990-12-21 HU HU734/91A patent/HU215383B/en unknown
-
1991
- 1991-03-06 CA CA002037607A patent/CA2037607C/en not_active Expired - Lifetime
- 1991-08-15 GB GB9117611A patent/GB2246781B/en not_active Revoked
- 1991-08-15 GB GB9117612A patent/GB2246570B/en not_active Expired - Lifetime
- 1991-08-19 NO NO19913228A patent/NO316076B1/en not_active IP Right Cessation
- 1991-08-19 NO NO91913229A patent/NO913229L/en not_active Application Discontinuation
- 1991-08-20 KR KR1019910700950A patent/KR100198478B1/en not_active IP Right Cessation
- 1991-08-20 FI FI913932A patent/FI108917B/en active
- 1991-08-20 NO NO19913271A patent/NO310560B1/en not_active IP Right Cessation
- 1991-08-20 FI FI913927A patent/FI108776B/en active
- 1991-08-20 BG BG95018A patent/BG60462B1/en unknown
- 1991-08-20 FI FI913926A patent/FI108777B/en active
- 1991-12-23 ZA ZA9110129A patent/ZA9110129B/en unknown
-
1993
- 1993-09-03 US US08/116,247 patent/US5929212A/en not_active Expired - Lifetime
- 1993-09-13 GB GB9318911A patent/GB2268744B/en not_active Expired - Lifetime
-
1994
- 1994-06-08 AU AU64612/94A patent/AU664801B2/en not_active Expired
-
1995
- 1995-10-12 GR GR950402787T patent/GR3017734T3/en unknown
-
1997
- 1997-12-22 JP JP9353861A patent/JPH11243955A/en active Pending
- 1997-12-24 GR GR970403432T patent/GR3025781T3/en unknown
-
1998
- 1998-11-23 NO NO985467A patent/NO985467D0/en not_active Application Discontinuation
- 1998-11-23 NO NO19985468A patent/NO316074B1/en not_active IP Right Cessation
-
1999
- 1999-04-19 FI FI990875A patent/FI109768B/en active
-
2003
- 2003-11-07 US US10/703,963 patent/US7244832B2/en not_active Expired - Fee Related
- 2003-11-07 US US10/704,071 patent/US7244615B2/en not_active Expired - Fee Related
- 2003-11-07 US US10/703,344 patent/US7262050B2/en not_active Expired - Fee Related
- 2003-11-07 US US10/704,352 patent/US7241877B2/en not_active Expired - Fee Related
-
2004
- 2004-09-10 US US10/938,117 patent/US20060029593A1/en not_active Abandoned
- 2004-09-10 US US10/937,949 patent/US20050136054A1/en not_active Abandoned
- 2004-09-10 US US10/937,971 patent/US20050123534A1/en not_active Abandoned
-
2005
- 2005-11-21 US US11/284,260 patent/US20060073136A1/en not_active Abandoned
- 2005-11-21 US US11/284,261 patent/US20060073137A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695459A (en) * | 1984-12-26 | 1987-09-22 | The Board Of Trustees Of Leland Stanford Junior University | Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells |
EP0328404A1 (en) * | 1988-02-12 | 1989-08-16 | Btg International Limited | Modified antibodies |
EP0365209A2 (en) * | 1988-10-17 | 1990-04-25 | Becton, Dickinson and Company | Anti-leu 3A amino acid sequence |
Non-Patent Citations (4)
Title |
---|
Nature, Vol. 332, March 1988 L. Riechmann et al.: "Reshaping human antibodies for therapy ", * |
Nature, Vol. 337, February 1989 D.J. Capon et al.: "Designing CD4 immunoadhesins for AIDS therapy ", * |
Proc. Natl. Acad. Sci. USA, Vol. 86, December 1989 C. Queen et al.: "A humanized antibody that binds to the interleukin 2 receptor ", * |
Scientific American, Vol., October 1988 J.N. Weber et al.: "HIV Infection: The Cellular Picture ", * |
Cited By (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US6982321B2 (en) | 1986-03-27 | 2006-01-03 | Medical Research Council | Altered antibodies |
US7022500B1 (en) | 1988-12-28 | 2006-04-04 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6180370B1 (en) | 1988-12-28 | 2001-01-30 | Protein Design Labs, Inc. | Humanized immunoglobulins and methods of making the same |
US7037496B2 (en) | 1989-12-27 | 2006-05-02 | Centocor, Inc. | Chimeric immunoglobulin for CD4 receptors |
US7098006B1 (en) | 1990-09-17 | 2006-08-29 | Burroughs Wellcome Co. | Chimeric antibody, pharmaceutical composition and process of its production |
WO1992005274A1 (en) * | 1990-09-17 | 1992-04-02 | Scott David Gorman | Framework mutated antibodies and their preparation |
USRE43898E1 (en) | 1990-09-17 | 2013-01-01 | Glaxo Wellcome Inc. Research | Altered antibodies and their preparation |
USRE46877E1 (en) | 1990-09-17 | 2018-05-29 | Btg International Limited | Altered antibodies and their preparation |
US6767996B1 (en) | 1990-09-17 | 2004-07-27 | Glaxo Wellcome Inc. | Altered antibodies and their preparation |
US5871732A (en) * | 1990-11-27 | 1999-02-16 | Biogen, Inc. | Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection |
WO1992015699A1 (en) * | 1991-03-04 | 1992-09-17 | Ks Biomedix Ltd. | High affinity humanized monoclonal antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US5821337A (en) * | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US6639055B1 (en) | 1991-06-14 | 2003-10-28 | Genentech, Inc. | Method for making humanized antibodies |
US6719971B1 (en) | 1991-06-14 | 2004-04-13 | Genentech, Inc. | Method for making humanized antibodies |
US8075890B2 (en) | 1991-06-14 | 2011-12-13 | Genentech, Inc. | Method for making humanized antibodies |
US6054297A (en) * | 1991-06-14 | 2000-04-25 | Genentech, Inc. | Humanized antibodies and methods for making them |
US6706265B1 (en) | 1992-03-24 | 2004-03-16 | Btg International Limited | Humanized anti-CD3 specific antibodies |
US5585097A (en) * | 1992-03-24 | 1996-12-17 | British Technology Group Limited | Humanized anti-CD3 specific antibodies |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
AU715052B2 (en) * | 1995-05-18 | 2000-01-13 | Johnson & Johnson Research Pty. Limited | Induction of immunological tolerance by the use of non-depleting anti-CD4 antibodies |
EP1161955A2 (en) * | 1995-05-18 | 2001-12-12 | Ortho Pharmaceutical Corporation | Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells |
WO1996036359A1 (en) * | 1995-05-18 | 1996-11-21 | Ortho Pharmaceutical Corporation | Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies |
EP1161955A3 (en) * | 1995-05-18 | 2001-12-19 | Ortho Pharmaceutical Corporation | Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells |
JP2008189691A (en) * | 1995-10-10 | 2008-08-21 | Genpharm Internatl Inc | Transgenic non-human animal producing heterologous antibody |
JP2008239630A (en) * | 1995-10-10 | 2008-10-09 | Genpharm Internatl Inc | Transgenic non-human animal producing heterologous antibody |
WO1997017374A1 (en) * | 1995-11-08 | 1997-05-15 | Medac Gesellschaft Für Klinische Spezialpräparate Gmbh | Recombinant ligands for the human cell membrane antigen cd30 |
EP2363484A3 (en) * | 1998-04-03 | 2012-04-25 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody |
AU2004222089B2 (en) * | 2003-03-21 | 2010-12-02 | Biotest Ag | Humanized anti-CD4 antibody with immunosuppressive properties |
EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
EP2070948A1 (en) * | 2003-03-21 | 2009-06-17 | Biotest Ag | Humanized Anti-CD4 antibody with immunosuppressive properties |
US9758581B2 (en) | 2003-03-21 | 2017-09-12 | Biotest Ag | Humanized anti-CD4 antibody with immunosuppressive properties |
US7452981B2 (en) | 2003-03-21 | 2008-11-18 | Biotest Ag | Humanized anti-CD4 antibody with immunosuppressive properties |
US8685651B2 (en) | 2003-03-21 | 2014-04-01 | Biotest Ag | Method for screening for an anti-CD4 antibody suitable for use in immunotherapy |
US8673304B2 (en) | 2003-03-21 | 2014-03-18 | Biotest Ag | Humanized anti-CD4 antibody with immunosuppressive properties |
US8586715B2 (en) | 2003-03-21 | 2013-11-19 | Biotest Ag | Humanized anti-CD4 antibody with immunosuppressive properties |
EP2332991A3 (en) * | 2003-03-21 | 2012-12-19 | Biotest AG | Humanized anti-cd4 antibody with immunosuppressive properties |
WO2004083247A1 (en) * | 2003-03-21 | 2004-09-30 | Biotest Ag | Humanized anti-cd4 antibody with immunosuppressive properties |
US8440806B2 (en) | 2003-03-21 | 2013-05-14 | Biotest Ag | Humanized anti-CD4 antibody with immunosuppressive properties |
US8663634B2 (en) | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
US9056906B2 (en) | 2006-06-14 | 2015-06-16 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
US7951920B2 (en) | 2006-08-17 | 2011-05-31 | Roche Palo Alto Llc | Conjugate of an antibody against CCR5 and an antifusogenic peptide |
US10729742B2 (en) | 2007-02-01 | 2020-08-04 | Universitätsmedizin Der Johannes Gutenberg-Universität Mainz | Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4 |
WO2008110332A1 (en) | 2007-03-13 | 2008-09-18 | F.Hoffmann-La Roche Ag | Peptide-complement conjugates |
EP2526972A1 (en) | 2007-07-20 | 2012-11-28 | F. Hoffmann-La Roche AG | A conjugate of an antibody against CD4 and antifusogenic peptides |
WO2009012944A1 (en) | 2007-07-20 | 2009-01-29 | F.Hoffmann-La Roche Ag | A conjugate of an antibody against cd4 and antifusogenic peptides |
US9334325B2 (en) | 2008-03-13 | 2016-05-10 | Biotest Ag | Method for treating psoriasis |
US9512226B2 (en) | 2008-03-13 | 2016-12-06 | Biotest Ag | Agent for treating disease |
US9550831B2 (en) | 2008-03-13 | 2017-01-24 | Biotest Ag | Method for treating psoriasis |
US9995733B2 (en) | 2009-11-30 | 2018-06-12 | Biotest Ag | Agents for treating disease |
US10125192B2 (en) | 2010-08-19 | 2018-11-13 | Zoetis Belgium S.A. | Caninized anti-NGF antibodies and their use |
US9505829B2 (en) | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
US10093725B2 (en) | 2010-08-19 | 2018-10-09 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
US9809647B2 (en) | 2010-11-19 | 2017-11-07 | Eisai R&D Management Co., Ltd. | Neutralizing anti-CCL20 antibodies |
WO2012166555A1 (en) | 2011-05-27 | 2012-12-06 | Nektar Therapeutics | Water - soluble polymer - linked binding moiety and drug compounds |
US9951128B2 (en) | 2012-06-06 | 2018-04-24 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
US11161906B2 (en) | 2013-07-25 | 2021-11-02 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
US10669337B2 (en) | 2014-07-25 | 2020-06-02 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
US11802158B2 (en) | 2014-07-25 | 2023-10-31 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
US10982002B2 (en) | 2018-03-12 | 2021-04-20 | Zoetis Services Llc | Anti-NGF antibodies and methods thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0460178B1 (en) | Cd4 specific recombinant antibody | |
US5861155A (en) | Humanized antibodies and uses thereof | |
US20020099179A1 (en) | Cdr-grafted antibodies | |
US5834597A (en) | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same | |
US7147851B1 (en) | Humanized immunoglobulin reactive with α4β7 integrin | |
JP2002514421A (en) | Antibodies to CD23, their derivatives, and their therapeutic use | |
KR20010034554A (en) | Cd147 binding molecules as therapeutics | |
KR20050111748A (en) | Humanized anti-cd4 antibody with immunosuppressive properties | |
KR20040020866A (en) | Silenced anti-CD28 antibodies and use therof | |
WO2024082178A1 (en) | Bispecific chimeric antigen receptor targeting cd19 and cd22 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB GR HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991901835 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 913932 Country of ref document: FI Ref document number: 2046904 Country of ref document: CA Ref document number: KR Ref document number: 148283 Country of ref document: RO |
|
WWP | Wipo information: published in national office |
Ref document number: 1991901835 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991901835 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 990875 Country of ref document: FI |
|
WWG | Wipo information: grant in national office |
Ref document number: 913932 Country of ref document: FI |
|
WWG | Wipo information: grant in national office |
Ref document number: 990875 Country of ref document: FI |